ANNUAL REPORT 2024



Versarien® PLC

Versarien plc (AIM: VRS) is an IP-led **advanced engineering** materials group that utilises proprietary technology to create innovative engineering solutions.

Versarien holds more than 110 patents covering areas including the manufacture and use of graphene and related materials (GRMs) in diverse applications. We develop and manufacture advanced materials and products globally through a number of subsidiaries and have the widest portfolio of high-quality verified products.

PRINCIPAL UNITED KINGDOM SUBSIDIARIES

Versarien® GRAPHENE

2-DTECH

CAMBRIDGE GRAPHENE

PRINCIPAL GLOBAL SUBSIDIARIES

Gnanomat

Versarien® 버자리언 코리아

Versarien Korea

The Graphene Council administers the Verified Graphene Producer® and the Verified Functionalized Graphene™ programs, the only credentials that include independent 3rd party in-person inspections of graphene production facilities, verification of production methods, volumes and quality control processes.

The Verified Graphene Producer® and Verified Functionalized Graphene™ programs also include independent expert testing of graphene materials by internationally recognised and qualified labs, such as the National Physical Laboratory (NPL) in the UK, according to the Graphene Classification Framework.

Versarien uses proprietary materials technology to create innovative engineering solutions that are capable of having game-changing impact in a broad variety of industry sectors.

Versarien was the first company in the world to pass the rigorous Verified Graphene Producer® program in 2019, and has been re-certified in 2022.

VERIFIED GRAPHENE® PRODUCER

THE GRAPHENE COUNCIL

WANT TO KNOW MORE? GET IN TOUCH TODAY

Visit our website at: www.versarien.com

Email us at: info@versarien.com

Write to us at: Units 1A-D
Longhope Business Park
Monmouth Road
Longhope
Gloucestershire
GL17 0QZ
United Kingdom

Call us on: +44 (0) 1594 887204

OUR PERIOD IN BRIEF

CONTINUING OPERATIONS KEY FINANCIAL HIGHLIGHTS

Group revenue (continuing operations)*

£2.4m

(2023: £3.0m)

Graphene revenues

£0.4m

(2023: £0.2m)

Adjusted LBITDA**

£1.7m

(2023: £3.0m)

Loss before tax

£4.3m

(2023: £14.1m)

Reported loss for the year

£4.3m

(2023: £14.2m)

Cash

£0.1m

(2023: £0.6m)

Gross raised via equity placings during the period

£2.0m

(2023: £3.4m)

* Excludes discontinued revenues of £2.6 million (2023: £2.5 million)

** Non GAAP measure described in full in the report on page 10

CONTENTS

Key Highlights

PARTNERSHIPS/COMMERCIALISATION HIGHLIGHTS

Construction

Cementene™

- Cementene™ is currently being tested with several large ready-mix and pre-cast concrete companies in the UK and Brazil. These trials aim to further refine the formulation and explore its potential for large-scale adoption.
- Following previous successful trials with Banagher Precast Concrete demonstrating a concrete mix with 21% reduction in cement content and maintaining the strength and durability of the mix, a traffic wall incorporating this mix was placed in a real operational environment, with periodic testing planned over 36 months to monitor long-term durability.

3D Construction Printing (3DCP)

- Contract to support the construction of the first UK 3D printed homes with Building for Humanity CIC.
- Delivered the "Physical & Mechanical Properties of 3D Printed Concrete" project to Office for Product Safety and Standards (OPSS).
- Through a partnership with AccXel, the UK's first industry-led construction school, the first apprentice has been onboarded, supporting the next generation of 3DCP professionals.

Energy

- Secured strategic contract with CBMM Technology Suisse SA, part of Brazil mining giant CBMM, to explore niobium-based Gnanocaps. This opens new business opportunities in applications demanding clean devices, such as offshore wind farms, maritime applications (ports), and as a safer alternative to explosion-risk technologies like Li-ion batteries.

Electronics

- Secured a distribution agreement for Graphene biosensors with A Barristor Company and MCK Tech (South Korea), paving the way for expanded commercialisation in the healthcare sector.

Technology Licensing

- Completed an agreement with MCK Tech (Korea) for the exclusive licence of five CVD graphene patents.
- Completed a know-how and manufacturing licence agreement with Montana Quimica LTDA, a Brazilian multinational focused on the production of paints and wood finishing products. In November 2024, Montana launched their advanced materials business unit SOMA.

GRANT FUNDING HIGHLIGHTS

- **iCARE:** Successfully passed the 18 month EC review of the 4-year long iCARE (Integrated Assessment and Advanced Characterisation of Neuro-Nanotoxicity) project (Horizon Europe) studying graphene in different use cases including graphene enhanced concretes and elastomers. Total grant value of £96,000.
- **BIOGUARD:** Cambridge Graphene was awarded an INN-PRESSME project to develop eco-friendly conductive inks for printed near-field communication (NFC) applications, commonly used for anti-counterfeit technology. The goal was to print on recyclable or biodegradable paper-based substrates, offering an alternative to plastic substrates with metallic antennas.
- **INNOVA:** Following the award of a €415,000 grant by ICEX Trade and Investment, Gnanomat designed, optimised and validated eco-friendly conductive inks for flexible, printed electronics. This funding supported the acquisition of a new pilot plant for manufacturing these functional inks.

CORPORATE HIGHLIGHTS

- Sold AAC Cyroma Ltd. for £550,000 payable in 16 equal quarterly instalments, with Versarien retaining a charge over the assets to secure the outstanding balance.
- Completed (post-period) the sale of CVD graphene plant and equipment to MCK Tech Co. Ltd. for £611,000 including interest payment, after a £6,000 warranty deduction.
- Increased shareholding in Gnanomat from 62% to 90%.

POST PERIOD HIGHLIGHTS

- Secured €804,000 grant from the Madrid government to continue developing GnanoCaps technology.
- Entered into a commercially funded project with Balfour Beatty Plc's Highways business to co-develop a range of UK supplied, low-carbon, graphene-infused 3D printable mortars designed for civil construction.
- Commissioned the Group's own concrete and mortar specimen testing equipment. This investment is accelerating the development of Cementene™ and supporting rigorous quality control for Versarien's 3DCP products.
- Industry Challenge Owner with Digital Catapult through The High Growth AI Accelerator for Innovate UK BridgeAI as part of the Construction Innovation Programme.
- Stephen Hodge, CEO, appointed as a member of the Royce 2D Materials Steering Group.

OUR PRODUCT PORTFOLIO

Product Line/Brand	Description
	ADVANCED MATERIALS
CVD Graphene	Chemical vapour deposition (CVD) is the process to manufacture truly single-layer graphene (SLG). Following the plant and equipment sale, we will continue to collaborate and obtain CVD graphene from MCK Tech using a rapid thermal CVD process (RT-CVD). Graphene synthesis and lamination, transfer and stacking are performed in Class 1000 (ISO 6) laboratories, whilst wet chemical etching and all graphene characterisation takes place in Class 10000 (ISO 7) laboratories. Potential applications of CVD graphene include sensors, membranes, transparent conductive electrodes, resistive heaters and use in high-frequency electronic, (opto)electronic and semi-conductor applications
Nanene™	Nanene™ is a high quality few-layer graphene powder, independently tested and passing the Graphene Council's Verified Graphene Producer® program. Nanene™ is a commercially available product that enables true leverage of graphene's unique properties. Nanene™ applications include use as an additive for thermoset, thermoplastic and rubber based composite materials, electrodes in lithium-ion batteries and fuel cells, solar PV cells, electrically conductive inks, thermal interface materials, concrete, metal-matrix composites, paints and coatings (corrosion protection, anti-fouling, UV resistant, barrier films, etc.).
Graphene Oxide (GO)	With a higher level of oxygen content ratio, our GO products are suitable for different applications where high aspect ratio and processability are key.
Hexotene™	Hexotene™ is our family of high quality hexagonal boron nitride (hBN) nanosheet powders. Hexotene™ is particularly useful for products where electrical conductivity is not desired, but many other features such as thermal conductivity and mechanical strength can be harnessed.
Hybrid Nanomaterials	Gnanomat develops novel hybrid nanomaterials combining graphene with metal (oxide) nanoparticles, for use in energy storage devices and beyond.
Graphinks™	Graphinks™ are graphene and related material inks and dispersions that bring multi-functionality (high electrical and thermal conductivity, fire retardation, UV protection, etc.), produced via a high pressure homogenisation process that offers high yield and uniform size distribution.
	POLYGRENE™ INTERMEDIATES
Thermoplastics	Versarien has developed an innovative graphene enhanced thermoplastic range, Polygrene™ with a wide portfolio of thermoplastic compounds and masterbatches that incorporate our advanced materials.
Thermosets	Versarien has extensive development experience with graphene enhanced thermoset composites using a variety of resins (epoxy, acrylic, alkyd, polyurethane, cyanate ester, etc.) and fibre materials (carbon, glass, flax, hemp, etc.), creating dispersions and masterbatches.
Elastomers	Versarien manufactures graphene enhanced rubber compounds with commercial footwear grades and developments ongoing in tyre, oil & gas and seal/gasket applications.

Product Line/Brand	Description
PRODUCTS, TECHNOLOGY PLATFORMS & SERVICES	
CONSTRUCTION	
Cementene™	Cementene™ is our family of graphene-based aqueous admixtures that promises to significantly enhance the properties of concrete and reduce its carbon cost. The benefits of Cementene™ include: increased compressive strengths, reduced CO_2 and cost (less material, less/no reinforcement), reduced material (thinner slab, less cover, reduced reinforcement), increased durability (low permeability/porosity leading to longer predicted life), additional early strength, highly workable concrete.
3D Construction Printing (3DCP)	Versarien is pioneering innovative robotic 3DCP methods. Through our UK-based production facility, we create 3D printed products for our clients across a range of sectors and applications, from landscape architecture to infrastructure. We also have the capability to mobilise our robot and print on site, to print in-situ or set up a 'flying factory' to reduce cost and/or CO_2 for large orders. Through our consultancy service, we also work with our clients to help them integrate 3DCP into their projects, from planning and developing a technological strategy through to design and implementation.
LEISURE	
Graphene-Wear™	Graphene-Wear™ comprises textile coatings and finishes that offer enhanced thermal and moisture management as well as optimised graphene enhanced footwear rubbers. Our customers are able to purchase mass-production-ready graphene ink formulations and infused rubber compounds that can be used within their upcoming ranges.
ENERGY	
GnanoCaps	GnanoCaps are Gnanomat's pseudocapacitors that incorporate optimised hybrid nanomaterials within the electrodes. GnanoCaps demonstrate superior performance compared to current supercapacitor market standards. Furthermore, GnanoCaps typically utilise aqueous electrolytes, mitigating environmental concerns associated with leakage and ensuring safe and sustainable operation. This opens new business opportunities in applications demanding clean devices, such as offshore wind farms, maritime applications (ports), and as a safer alternative to explosion-risk technologies like Li-ion batteries in aircraft environments or in the presence of flammable liquids/gases.
ELECTRONICS	
Sensors	Versarien has recently launched a new biosensor chip utilising novel graphene barristor sensor platform technology. These graphene barristor devices, developed in South Korea by A Barristor Company (ABC), will utilise CVD grown graphene that is produced under a Versarien licence. Versarien has signed a distribution agreement with ABC to distribute the products in the UK and Europe. The products can be supplied as individual chips or on a wafer scale. The range of sensor products to be distributed by Versarien may be expanded at a later date based on ABC's product developments, such as in infrared detection, gas/chemical detection, temperature detection or multiple sensor on a chip technology.
COMMERCIAL R&D	
Our UK and Spanish R&D teams (Cambridge Graphene, 2-DTech and Gnanomat) provide R&D services to support companies developing new products containing advanced materials or to perform detailed material or product testing. Key examples this year have included 9 month funded projects with CBMM (Brazil) and IRPC (Thailand) that have utilised resources available to all three subsidiaries.	

To find out more visit versarienproducts.co.uk
Technical datasheets can be downloaded from: versarienproducts.co.uk/downloads-centre

CHAIR'S STATEMENT

Diane Savory OBE
Non-executive Chair

The last 12 months have continued to see Versarien progress as we continue to focus on a cost-effective path to commercial success and financial viability.

We have made progress with our asset sales having sold the Korean plant for £604,000 and have to date received all the monies plus interest due. AAC Cyroma Ltd has been sold for £550,000 payable in 16 quarterly instalments of £34,000 the first of which has been received. The remaining asset sale is that of Total Carbide Ltd which we still continue to market.

Our strategy continues to be that of a development led advanced materials company focused on specific sectors that will lead to a manufacturing-light and licensing model and it is pleasing to report that our pipeline of opportunities continues to grow. It is particularly pleasing that Gnanomat, our Spanish subsidiary received a grant, paid in advance of £663,000 post period end to finance a project relating to next generation energy storage devices based on Gnanomat's advanced materials technology.

Whilst the Group still remains loss making at present it has made significant progress in reducing its losses with LBITDAE on continuing operations over the last 12 months decreasing from £3 million in the 2023 financial year, to £1.7 million in the year under review.

Repayment of the IUK loan of £5 million was due to commence in 2025 and it is pleasing to note that agreement has been reached with Innovate UK to defer capital repayments until August 2026.

Overall, it is pleasing to see the progress the Group has made under the leadership of the Chief Executive Officer, Dr. Steve Hodge and we have reached an appropriate point in time to reflect upon the composition of the Board and plan for the future, albeit that there are still some immediate financial challenges to overcome. With this in mind we are now looking at how the Board might be strengthened to support Steve as we move forwards under our manufacturing-light and licensing business model.

I am grateful for the support we continue to receive from both new and existing shareholders and to all our staff as we continue to transition the business into an IP led licensing model and we look forward to updating the market on future developments in due course.

Diane Savory OBE
Non-executive Chair

26 March 2025

Dr Stephen Hodge
Chief Executive Officer

The past year has been a transformative one for Versarien, as we have continued aligning our operations with a more streamlined, manufacturing-light, and licensing-driven model. While graphene remains the cornerstone of our innovation, we're proud to utilise the full spectrum of advanced material properties to optimise product performance for our clients across a range of industries.

Our strategic restructuring efforts have significantly reduced operating costs, allowing us to channel resources into our core advanced materials businesses. By focusing on high-potential sectors and divesting non-core operations, we are building a stronger foundation for sustainable growth and commercial success.

OPERATIONS

Divesting our mature businesses has been a key part of our strategy. After exploring the possibility of selling AAC Cyroma and Total Carbide together, we found that their distinct operations and customer bases made a joint sale impractical. After a lengthy process, on 30 September 2024, we announced the sale of AAC Cyroma. Discussions regarding the sale of Total Carbide are ongoing and we remain committed to finding the right buyer.

As part of our transition to a licensing-focused model, we entered into an agreement in March 2024 to sell our CVD graphene plant and equipment to MCK Tech Co. Ltd., concluded in February 2025. This deal includes a five-year exclusive licensing agreement for five of our patents, underscoring our ability to monetise our innovations while continuing to collaborate with industry leaders.

AREAS OF FOCUS

Previously, Versarien was a member of the European Commission's Graphene Flagship project. Recently, with the implementation of the EC strategy on "Advanced Materials for Industrial Leadership", a new Europe-wide Research and Innovation ecosystem has emerged known as the Innovative Advanced Materials Initiative ("IAM-I"). The hope is that IAM-I will significantly accelerate the time-to-market of sustainable innovative advanced materials and associated technologies designed for a digital circular economy. As a Full Member of the initiative, Versarien attended the 1st General Assembly, in which IAM-I's governing bodies (Executive Board and Association Delegation) were constituted on 31 January 2025.

IAM-I's Strategic Research & Innovation Agenda (SRIA) outlined four priority areas for research and innovation that included Construction, Energy, Mobility and Electronics. As a company, Versarien is already aligned with these areas and I believe continuing to do so will put us in a good position in the coming years.

In the UK, it has been great to see the Henry Royce Institute for Advanced Materials (Royce) launching the National Materials Innovation Strategy in January 2025, outlining materials innovation priorities through six "Opportunity Themes" which will deliver high-impact innovation into the UK economy: 1. Energy Solutions, 2. Future Healthcare, 3. Structural Innovations, 4. Advanced Surface Technologies, 5. Next-Generation Electronics, Telecommunications & Sensors and, 6. Consumer Products, Packaging & Specialist Polymers. Similarly, Versarien is pursuing opportunities and developments in a number of these areas, with the goal to be at the forefront and support the UK achieve its innovation and decarbonisation ambitions.

Leading on from this, I have been honoured to have been appointed as a member of the Royce 2D Materials Steering Group. The steering group will meet 2–3 times a year to discuss national priorities for 2D materials research and to assist the Royce Institute in developing strategies for advancing this field.

More information about IAM-I can be found here: https://www.iam-i.eu/

More information about the National Materials Innovation Strategy can be found here: https://www.royce.ac.uk/collaborate/innovationstrategy/

SECTORS

Construction

Cement production accounts for a staggering 8% of global CO_2 emissions, making it one of the most significant contributors to climate change. At Versarien, we are tackling this challenge head-on by developing innovative graphene-based admixtures, to enable the production of low-carbon concrete. Cementene™, a family of water-based admixtures containing graphene, has demonstrated improvements across a range of concrete mix designs. Versarien continues to lead the way in modern methods of construction (MMC), with our ambition to fully integrate 3D Construction Printing (3DCP) with graphene-enhanced materials to deliver sustainable, efficient, and innovative solutions. Our recently announced 3DCP projects and partnerships underscore our commitment to transforming the construction industry. We are proud to support Building for Humanity CIC in delivering the UK's first social housing project of its kind using 3DCP. This project represents a groundbreaking application of 3DCP technology, with significant implications for the future of affordable and sustainable housing in the UK. Working with Balfour Beatty's Highways business we are assessing performance, durability, and cost-effectiveness of 3DCP compared to traditional construction. This collaboration is setting the stage for a future technology showcase in 2025, emphasising the scalability and potential of graphene-enhanced 3DCP materials. We are actively engaging with regulators and fostering talent to ensure 3DCP's successful adoption in the UK.

Following the July 2024 fundraise, we have made significant investment in concrete and mortar testing capabilities. The new testing equipment, commissioned in January 2025 will improve our know-how and confidence in pushing towards Cementene™ product approval as a chemical admixture in concrete and for quality control of our 3DCP products. It was great to see our 3DCP Lead Operative, Aneta, shortlisted for the Women in Construction 2024 "On The Tools" Award, recognising her contributions to the field. Through a partnership with AccXel, the UK's first industry-led construction school, we've onboarded our first apprentice, supporting the next generation of 3DCP professionals. By integrating advanced materials, regulatory expertise, and cutting-edge technologies, Versarien is paving the way for graphene and 3DCP to revolutionise the UK's construction industry.

Energy & Mobility
In the past year, Gnanomat has achieved remarkable milestones, underscoring its leadership in nanomaterial innovation. One of the standout accomplishments was the successful development of GnanoCaps - advanced energy storage devices leveraging Gnanomat's cutting-edge technology. These devices, based on sustainable, high-performance nanomaterials, promise superior energy efficiency and longer lifecycles, positioning Gnanomat at the forefront of next-generation energy solutions. On the commercialisation front, Gnanomat secured a strategic contract with Brazilian mining giant CBMM that could accelerate the adoption of GnanoCaps in key regions. With the recent awarding of an €804,000 grant awarded by the Madrid government, we're positioning ourselves as leaders in safe, sustainable energy storage.

Electronics
Versarien is making significant strides in the electronics sector, utilising advanced materials like graphene to create multifunctional products that push the boundaries of innovation. Our Graphinks™ are high-performance inks and dispersions made from graphene and related materials (GRM), offering a range of benefits. The demand for Graphinks™ continues to grow, particularly in the development of prototype electronic devices such as wearable heaters using PET and Dupont™ Intexar™ substrates. Our efforts to develop eco-friendly conductive inks, as seen in Cambridge Graphene's BIOGUARD and Gnanomat's INNOVA projects, are gaining momentum. Gnanomat expanded its product portfolio with the launch of a new business line focused on conductive inks that offer significant advantages, and expand possible applications in printed electronics.

Our ongoing collaboration with MCK Tech plays a key role in the development of innovative electronic devices and products. We recently secured a distribution agreement for graphene biosensors developed in South Korea by A Barristor Company that will utilise CVD grown graphene that is produced under a Versarien licence by MCK Tech. This partnership further strengthens our position in the growing sensor market with graphene-based sensors expected to play an increasing role in healthcare, environmental monitoring, and other critical applications.

CURRENT TRADING AND OUTLOOK

We continue to make substantial progress across our core sectors, driven by our strategic focus on advanced materials. Our innovative technologies, combined with disciplined cost management and operational efficiency, have positioned us for sustained growth. Based on our current forecast, we anticipate the Group reaching break even at the EBITDA level towards the end of the current financial year.

We are excited about the opportunities ahead, particularly with Cementene™ in construction, GnanoCaps in energy storage, and the growing adoption of Graphinks™ and CVD graphene-based sensors in electronics. Our ability to innovate and leverage our expertise in advanced materials fuels our optimism for the future. Focused on nurturing talent, expanding product offerings, and strengthening partnerships with global leaders, our shift to a manufacturing-light model ensures continued growth and innovation.

As mentioned in the Chair's statement, I am looking at how we might strengthen the Board with non-executive directors with particular sector experience.

I am confident that our strategic direction, combined with our focus on commercialising intellectual property and securing strong partnerships, will help us navigate challenges and deliver robust growth. Our diverse portfolio of technologies is setting the stage for continued success, and we look forward to reporting further progress through 2025.

Dr Stephen Hodge
Chief Executive Officer

26 March 2025

A structure to **deliver**

Versarien plc seeks to capitalise on innovative IP, transforming it into commercially viable products that can tackle the technological challenges faced by modern manufacturers.



Strategic objectives and KPIs

Commercialisation of our advanced materials and technologies utilising a manufacturing-light and licensing model remains the objective of the Board.

	Period progress	Future strategy
Entering into global technology licensing agreements to support the implementation and scale up of our advanced materials and technologies	Licensing agreements were signed as described in the operational highlights	We continue to look for opportunities both in the UK and overseas
Supply graphene enhanced products to a number of sectors	Supply is concentrated on the development of the construction, energy and electronics markets	To align with the strategic objectives of the Innovative Advanced Materials Initiative (IAM-I)
Enter into supply agreements to distribute advanced materials and products	We have entered into a UK and EU distribution agreement to supply CVD graphene barristor biosensor chips following the sale of our Korean equipment	We continue to look for opportunities to distribute advanced materials and technologies that would complement or enhance our existing product portfolio
Develop and enhancing our 3D Construction Printing capability in the UK	Delivery of 3DCP products and ongoing materials development agreement with Balfour Beatty Plc post period	To develop robust UK supply chains for 3DCP materials and continue to deliver 3DCP solutions across a number of sectors

As a Group we concentrate on the following financial metrics:

Continuing Operations	**12 months to 30 September 2024 £'000**	**12 months to 30 September 2023 £'000**
Group revenue	2,424	2,983
Gross margin percentage	29%	21%
Loss before interest, tax, depreciation, amortisation, exceptional costs, share based charges and other gains/losses	(1,749)	(3,027)
Cash used by Technology businesses	(1,397)	(3,087)
Cash used by Mature businesses	(414)	(428)
Cash generated by parent (before loans to/from subsidiaries)	1,360	2,760
(Decrease) in cash and cash equivalents	(451)	(755)

Christopher Leigh
Chief Financial Officer

AAC Cyroma Ltd was sold during the period and consequently these results are split between continuing and discontinued operations.

Group results

Revenues from continuing operations were £2.42 million (2023: £2.98 million). Revenue from the technology business was £0.38 million (2023: £0.24 million). The loss from operations was £3.83 million (2023: £13.61 million).

The adjusted LBITDA for continuing operations was £1.75 million compared to £3.03 million for the prior period and is shown in the table below. Adjusted LBITDA (which is not a GAAP measure and is not intended as a substitute for GAAP measures and may not be the same as that used by other companies) is a measure used by management to reflect the core operating performance of the underlying businesses rather than the effects of non-core financial and non-cash expenses. The adjustments to the loss from operations as disclosed in the Group Statement of Comprehensive Income relate to depreciation and amortisation, share based payment charges and exceptional items.

Exceptional items of £0.84 million in the year (£2023 £8.77 million) relate to net gains from the sale of AAC Cyroma Ltd of £0.35 million, restructuring costs of £0.30 million and asset impairment provisions at Total Carbide Ltd of £0.89 million. In the prior year the exceptional charge related to an impairment review of goodwill, impairment of development costs and tangible assets as a result of the delay in market traction, the Company's market capitalisation and also to align with the turnaround strategy.

The reported loss before tax for continuing operations was £4.30 million (2023: £14.12 million). Group net assets at 30 September 2024 were negative £1.16 million (30 September 2023: £1.08 million) with cash at the period end of £0.15 million (30 September 2023: £0.6 million).

Net cash used in operating activities was £1.72 million (2023: £2.74 million). Net investment in intangible assets and equipment was £0.1 million (2023: £0.34 million) and net principal lease payments were £0.46 million (2023: £0.81 million) giving total cash outflows of £2.28 million (2023: £3.89 million).

These activities were financed by net funds received from the issue of shares £1.91 million (£3.13 million) less net loans repaid of £0.05 million (2023: £0.1 million net loans repaid) and proceeds from the disposal of assets held for sale £0.3 million (2023: £nil) totalling £2.16 million (2023: £3.03 million).

The deficit of £0.12 million (2023: £0.86 million deficit) together with a decrease on drawings on the invoice finance facilities of £0.33 million (2023: £0.1 million increase) thus reduced cash at the year-end by £0.45 million (2023: £0.76 million).

Post year-end repayment of the Innovate UK loan of £5 million has been rescheduled to commence in August 2026, and any associated covenants rescheduled.

	Year to September 2024			Year to September 2023		
Adjusted LBITDA	**Continuing operations £'000**	**Discontinued operations £'000**	**Total £'000**	**Continuing operations £'000**	**Discontinued operations £'000**	**Total £'000**
(Loss) from operations	(3,833)	(94)	(3,927)	(13,609)	(107)	(13,716)
Depreciation and Amortisation	1,094	67	1,161	1,286	124	1,410
Share based payments	147	–	147	530	–	530
Exceptional items	843	–	843	8,765	–	8,765
Adjusted LBITDA	(1,749)	(27)	(1,776)	(3,028)	17	(3,011)

Funding

Settlement of the sale of the Korean plant and machinery has been ongoing and full payment made post year-end. AAC Cyroma Ltd has been sold for £550,000 deferred consideration payable in 16 equal instalments commencing December 2024. We continue to market Total Carbide Ltd.

The Group continues to apply for grant funding to support its development expenditure and grants received can vary from 70% to 100% contribution of project costs. Post year end, Gnanomat received an up-front grant of €804,000 (approximately £663,000) to finance a project relating to next generation energy storage devices based on Gnanomat's advanced materials technology. This is expected to support its operations for 24 months.

The Group is not taking on any new debt facilities and is pleased to report that the Innovate UK has agreed to reschedule capital and deferred interest repayments to August 2026.

In the General Meeting held on 24 March 2025, Shareholders approved resolutions to give the Directors' authority to allot 2.99 billion shares without pre-emption-rights.

Going Concern

The financial statements have been prepared on a going concern basis, and are subject to the matters described in the Accounting Policies note on page 38.

Christopher Leigh
Chief Financial Officer

26 March 2025

Managing risks **effectively**

The following risks are those that the Group considers could have the most serious adverse effect on its performance and reputation.

	Risk	Mitigation	Change
1	**TECHNOLOGICAL RISKS** Versarien plc operates in an industry where competitive advantage is heavily dependent on technology. It is possible that technological development may reduce the importance of the Group's function(s) in the market or render the patents and licences on which it relies redundant. The Group's existing products may become obsolete or may be superseded by new technologies or changes in customer or end-user requirements.	Versarien plc continually monitors the market in which it operates and has the technical resources to invest in new technology as appropriate.	—
2	**COMPETITION RISKS** New competitive products, designs or solutions may enter the market with different benefits or using different technologies, making them equally or more attractive than the Group's current range of products. Competitors may also be able to devote greater resources to the promotion and sale of their products, designs or solutions than the Group, which would give them a competitive advantage.	The Group continues to employ technical resources with the aim of improving its products. If the Group is unable to compete successfully with existing or new competitors, it may have to reduce prices on products, which would lead to reduced margins.	—
3	**INTELLECTUAL PROPERTY PROTECTION RISKS** Failure to protect the Group's IP may result in another party copying or otherwise obtaining and using its proprietary content and technology without authorisation. There may not be adequate protection for IP in every country in which the enlarged Group's products are or will be made available and policing unauthorised use of proprietary information is difficult and expensive.	The Group monitors products brought to market as far as reasonably possible and will take cost-effective legal action to protect its intellectual property.	—
4	**DEVELOPMENT RISK** The rate at which the development of the Group's technology is adopted by potential customers is dependent upon the rate at which those customers wish to progress.	The Group mitigates this risk as far as possible by ensuring that it responds rapidly to technical changes that may be required.	—
5	**ATTRACTION AND RETENTION OF KEY EMPLOYEES RISKS** The Group depends upon the continued service and performance of the Executive Officers and key employees and, whilst it has entered into contractual arrangements with these individuals with the aim of securing the services of each of them, retention of these services cannot be guaranteed. The loss of the services of any of the Executive Officers or other key employees could damage the Group's business. Equally, the ability to attract new employees and senior employees with the appropriate expertise and skills cannot be guaranteed.	Risk is partially mitigated by providing opportunities for career advancement.	—

KEY:

Decrease · No change · Increase

	Risk	Mitigation	Change
6	**FUNDING RISKS** The Group will need to raise extra capital in the near future to bridge to profitability. No assurance can be given that any such additional financing will be available or that, if available, it will be available on terms favourable to the Group or to the Group's shareholders.	In the current environment it is not possible to mitigate the risk other than by approaching past participants in fund raises and by seeking strategic investment or longer term investment from tax efficient funds or to raise funds from the sale of assets.	▲
7	**GENERAL ECONOMIC CONDITIONS RISKS** Market conditions, particularly those affecting technology companies, may affect the ultimate value of the Group's share price regardless of operating performance. Market perception of technology companies may change, which could impact on the value of investors' holdings and impact on the ability of the Group to raise further funds by an issue of further shares. General economic conditions may affect exchange rates, interest rates and inflation rates. Movements in these rates will have an impact on the Group's cost of raising and maintaining debt financing.	Risk is mitigated by seeking to expand the products and technologies for sale within the Group and by seeking to sell the Group's products to wider geographical areas both directly and through distribution.	—
8	**COMMODITY PRICES RISKS** A significant amount of Versarien's purchases are metallurgical powders. Consequently, exposure to movements in underlying commodity prices affects margins.	At this stage it is not considered cost effective to utilise forward contracts to mitigate the risk. However, where possible we purchase from more than one source and manage our stock levels accordingly.	—
9	**BREXIT** Versarien has relationships with the EU and the impact from Brexit could negatively affect trade regulations, people, contracts, IP and European Grants.	So far as is possible, the company mitigates this risk by having a European subsidiary	—

Section 172 statement

Section 172(1)(a) to (f) of the Companies Act 2006 requires Directors to act in good faith, in a way that will promote the success of the Company for the benefit of its members as a whole, as well as having the regard to the specific matters below, some of which are also described on pages 18 to 21 of the best practice governance report.

A. THE LIKELY CONSEQUENCES OF ANY DECISION IN THE LONG TERM

Versarien plc's continued strategy is to seek to capitalise on innovative IP, transforming it into commercially viable products that can tackle the technological challenges faced by modern manufacturers. The day-to-day management of our subsidiary businesses is undertaken by the senior team within the businesses.

B. THE INTERESTS OF THE COMPANY'S EMPLOYEES

Our directly employed workforce is experienced in the individual markets in which it operates. The Board believes that its employees are key stakeholders within the Group and as such welcomes any feedback, particularly through feedback via the head of each business unit.

C. THE NEED TO FOSTER THE COMPANY'S BUSINESS RELATIONSHIPS WITH SUPPLIERS, CUSTOMERS AND OTHERS

Operating with fairness and integrity we work with our supply chain to develop a working relationship which benefits all parties. The Board recognises that the success of the Company is reliant upon all stakeholders in its business. UK Group companies are ISO 9001 accredited which involves processes to monitor and record feedback from suppliers and customers.

D. THE IMPACT OF THE COMPANY'S OPERATIONS ON THE COMMUNITY AND ENVIRONMENT

The Board considers environmental protection to be a high priority and has in place an environmental policy where the focus is on minimizing the impact of its activities and operations on the local, regional and national environments.

E. THE DESIRABILITY OF THE COMPANY MAINTAINING A REPUTATION FOR HIGH STANDARDS OF BUSINESS CONDUCT

The Board aims to lead by example and do what is in the best interests of the Company, its stakeholders and shareholders. The Directors strive to act in a manner which is professional and ethical and have published ethical policies for all employees to observe and comply with.

F. THE NEED TO ACT FAIRLY AS BETWEEN MEMBERS OF THE COMPANY

The Company communicates with shareholders through the Annual Report and Accounts, full-year and half-year announcements, General Meetings, release of news via LSE channels and by occasional podcasts and webinars. All members become privy to any price sensitive information at the same time and are treated equally in all respects. The company has three non-executive directors including the Chair and two executive directors to ensure fair corporate governance.

EQUAL OPPORTUNITIES

We offer equal opportunities regardless of gender, gender identity or reassignment, disability, religion or sexual orientation.

The key Board decisions made in the period are set out below:

Significant events/ decisions	Key s172 matter(s) affected	Actions and impact
Funding	Shareholders, employees	• Before raising equity the Company exhausted avenues for significant grant funding. • The Company continues to raise money on the equity markets at discounted prices.
Strategic direction	Shareholders, employees	• The reduced funding has resulted in the Board deciding to focus on those projects which are at the most advanced technology readiness level and which provide the best opportunity for commercialisation.

Dr Stephen Hodge
Chief Executive Officer

26 March 2025

INTRODUCTION TO CORPORATE GOVERNANCE

Diane Savory OBE
Non-executive Chair

COMPLIANCE APPROACH
The Board has adopted the Quoted Companies Alliance (QCA) Corporate Governance Code.

BOARD EFFECTIVENESS
The Board meets regularly to determine the policy and business strategy of the Group.

The Chief Executive Officer leads the development of business strategies within the Group's operations.

The Audit Committee meets, together with the wider Board, to consider the scope of the annual audit and the interim financial statements and to assess the effectiveness of the Group's system of internal controls. It reviews the results of the external audit, its cost effectiveness and the objectives of the auditors.

Given the size of the Group, the Audit Committee considers an internal audit function is not currently justified. The Audit Committee is chaired by Susan Bowen.

The Non-executive Directors are the members of the Remuneration Committee. It meets to determine Company policy on senior Executive remuneration, to make detailed recommendations to the Board regarding the remuneration packages of the Executive Directors.

The Chief Executive Officer is consulted on remuneration packages and policy but does not attend discussions regarding his own package.

The remuneration and terms and conditions of the appointment of Non-executive Directors are determined by the Board. The Remuneration Committee is chaired by Sir Iain Gray CBE.

The Board has considered mechanisms by which the business and the financial risks facing the Group are managed and reported to the Board.

The principal business and financial risks have been identified and control procedures implemented. The Board acknowledges its responsibility for reviewing the effectiveness of the systems that are in place to manage risk and to provide reasonable but not absolute assurance with regard to the safeguarding of the Group's assets against misstatement.

The key elements of the system of internal control are:

- clear definition of delegated authorities;
- preparation of budgets and forecasts for Board approval;
- close involvement of senior management in the day-to-day business of the Group; and
- regular reporting of business performance to the Board and the review of results against budget.

THE BOARD
The Board comprises Diane Savory OBE, Dr Stephen Hodge, Christopher Leigh, Sir Iain Gray CBE and Susan Bowen. The Board considers that there is an appropriate balance between the Executives and Non-executives and that no individual or small group will dominate the Board's decision making. The Board's members have a wide range of expertise and experience and it is felt that concerns may be addressed to the Non-executive Directors. The Board has delegated certain authorities to Committees, each with formal terms of reference. The whole Board acts as a Nomination Committee.

Diane Savory OBE
Non-executive Chair

26 March 2025

Experience and drive

Our leadership team is accomplished and experienced to lead the development of business strategies within the Group's operations.

DR STEPHEN HODGE

Chief Executive Officer

Dr Stephen Hodge was appointed Versarien CEO in July 2023 having been previously appointed to the board as CTO in January 2021. Stephen joined Versarien as Head of Research in July 2018 following Versarien's acquisition of Cambridge Graphene Limited where Stephen was a Principal Engineer. He has also held post-doctoral research associate positions at the Cambridge Graphene Centre, a research centre attached to the Department of Engineering at the University of Cambridge and in the Department of Chemistry at Imperial College London, where he also completed a PhD in Nanomaterial Chemistry. In 2022, Stephen was awarded the Royal Society of Chemistry "Rising Star in Industry Award" for strategic leadership in developing greener solutions and advocating for global regulations related to the physical and toxicological testing of graphene.

Advisory boards/committee memberships:

- Member of the Royce 2D Materials Steering Group
- Chairman of the Technical Working Group within the Graphene REACH registration consortium
- Member of the Graphene Flagship's ECHA/REACH committee
- Member of University of Manchester's Graphene NowNanoCDT International advisory board
- Alliance Engagement Lead for Versarien in National Highways' Roads Research Alliance

CHRISTOPHER LEIGH

Chief Financial Officer

Christopher is a chartered accountant with a significant track record in the manufacturing and engineering sector. His expertise covers corporate finance, mergers and acquisitions, post-acquisition integration, organisational restructuring and change management. He has previously held board-level positions in a variety of companies.

DIANE SAVORY OBE

Non-executive Chair

Diane recently served as Chair at GFirst Local Enterprise Partnership (Gloucestershire) which was responsible for driving economic growth across the region. Previous to this she worked for 22 years with the fashion brand and retailer Superdry, taking it from SME to a global brand floating on the London Stock Exchange in 2010. Diane currently chairs multiple businesses and charities across the county.

SUSAN BOWEN

Non-executive Director

Susan is CEO of the Digital Catapult and was previously president and CEO of Aptum Group, a Canadian headquartered company providing managed IT services. Prior to joining Aptum Group, she spent over 16 years at Hewlett Packard. Susan has also held a number of non-executive board positions including TechUK and Jisc Technologies.

SIR IAIN GRAY CBE

Non-executive Director

Iain was initially with British Aerospace before becoming managing director of Airbus UK. After 27 years in the aerospace sector, Iain was appointed Chief Executive of Innovate UK in 2007. He is an Emeritus Professor at Cranfield University having been their Director of Aerospace for over 9 years. He is a fellow of the Royal Academy of Engineering, fellow of the Royal Aeronautical Society and fellow of the Royal Society of Edinburgh and was Knighted in The Birthday Honours for 2023.

Best practice governance

We follow the Quoted Companies Alliance (QCA) Corporate Governance Code in line with the London Stock Exchange's AIM Rules requiring all AIM-listed companies to adopt and comply with a recognised corporate governance code. This report sets out our current compliance and explains the reasons for any Code departures.

PRINCIPLE 1: ESTABLISH A STRATEGY AND BUSINESS MODEL WHICH PROMOTES LONG-TERM VALUE FOR SHAREHOLDERS

Versarien plc seeks to be a development led advanced materials company focused on specific sectors that will lead to a manufacturing-light and licensing model

We do this through:

- applying for suitable grants to support development work;
- applying the management team's experience to developing and commercialising the advanced materials technology;
- utilising our plant and equipment for small scale production;
- collaborating with users in specific sectors such as construction and textiles; and
- licensing our technology.

We continue to sign application development agreements with customers and to build new relationships with global companies to incorporate graphene into their applications with a view to licensing our technology and brands.

PRINCIPLE 2: SEEK TO UNDERSTAND AND MEET SHAREHOLDER NEEDS AND EXPECTATIONS

The Company is committed to open communication with its shareholders to ensure that its strategy, business model and performance are clearly understood.

We do this via our Financial PR advisors and by reporting news via LSE channels.

The General Meetings ("GM") are the main forum for dialogue between shareholders and the Board.

Notices of Meetings are sent to shareholders at least 14 days before the meeting. For each GM resolution, the proxy results are announced at the meeting. The results of the GM are subsequently published on the Company's corporate website/ released via the Regulatory News Service.

The Board as a whole is kept informed of the views and concerns of shareholders by the CEO.

PRINCIPLE 3: TAKE INTO ACCOUNT WIDER STAKEHOLDER AND SOCIAL RESPONSIBILITIES AND THEIR IMPLICATIONS FOR LONG-TERM SUCCESS

Apart from our shareholders, our suppliers, customers and employees are considered to be our most important stakeholder groups. UK Group companies are ISO 9001 accredited which involves processes to monitor and record feedback from suppliers and customers.

The Group has in place an ethical policy which is applied at each Group company.

PRINCIPLE 4: EMBED EFFECTIVE RISK MANAGEMENT, CONSIDERING BOTH OPPORTUNITIES AND THREATS, THROUGHOUT THE ORGANISATION

The principal business and financial risks have been identified and control procedures implemented. The Board acknowledges its responsibility for reviewing the effectiveness of the systems that are in place to manage risk and to provide reasonable but not absolute assurance with regard to the safeguarding of the Group's assets against misstatement.

The key elements of the system of internal control are:

- clear definition of delegated authorities;
- preparation of annual budgets for Board approval;
- close involvement of senior management in the day-to-day business of the Group; and
- regular reporting of business performance to the Board and the review of results against budget.

All material contracts are required to be reviewed and signed by an Executive Director of the Company and reviewed by our legal advisers as appropriate.

Each individual UK company within the Versarien Group maintains its own risk register as part of its ISO 9001 certification to address key risks that may have an immediate impact.

Our ethical policy deals with compliance with laws and regulations, fair dealing and business intelligence, improper payments, business entertaining and duty to report violations.

PRINCIPLE 5: MAINTAINING THE BOARD AS A WELL-FUNCTIONING, BALANCED TEAM LED BY THE CHAIR

The Board comprises the Non-executive Chair, the Chief Executive Officer, the Chief Financial Officer/Company Secretary and two Non- executive Directors. The Board considers that the Non- executive Directors bring an independent judgement to bear.

The Board believes there is a suitable balance between independence on the one hand and knowledge of the Company on the other. The Board continues its practice of ensuring matters reserved for the Board are fully discussed and debated.

All Directors are encouraged to use their independent judgement and to challenge all matters, whether strategic or operational. The Group holds regular Board meetings as disclosed in the table below, and each Director is asked to disclose any conflicts of interest.

ATTENDANCE AT MEETINGS DURING THE PERIOD

	Board	Audit Committee*	Remuneration Committee
Diane Savory OBE	32/39	1/1	1/1
Dr Stephen Hodge	38/39	1/1	1/1
Christopher Leigh	38/39	1/1	1/1
Susan Bowen	32/39	1/1	1/1
Sir Iain Gray CBE	32/39	1/1	1/1

* Audit Committee matters may also be discussed as part of the regular board meetings.

PRINCIPLE 6: ENSURE THAT BETWEEN THEM THE DIRECTORS HAVE THE NECESSARY UP-TO-DATE EXPERIENCE, SKILLS AND CAPABILITIES

The Board is satisfied that, between the Directors, it has an effective and appropriate balance of skills and experience and time to perform its duties. Board members are able to attend such courses or training, as they feel appropriate, to keep up to date. Directors receive regular and timely information on the Group's operational and financial performance with information being circulated to the Directors in advance of meetings. The business reports regularly on its headline performance against its agreed budget.

All Directors retire by rotation at regular intervals in accordance with the Company's Articles of Association. The Company's Articles of Association require that one-third of the Directors must stand for re-election by shareholders annually in rotation and that any new Directors appointed during the year must stand for election at the AGM immediately following their appointment.

All Directors are able to take independent professional advice in the furtherance of their duties, if necessary, at the Company's expense. In addition, the Directors have direct access to the advice and services of the Company Secretary.

PRINCIPLE 7: EVALUATE BOARD PERFORMANCE BASED ON CLEAR AND RELEVANT OBJECTIVES, SEEKING CONTINUOUS IMPROVEMENT

The Chair, together with the non-executive directors are responsible for performing informal continuous assessment.

PRINCIPLE 8: PROMOTE A CULTURE THAT IS BASED ON ETHICAL VALUES AND BEHAVIOURS

The Board aims to lead by example and do what is in the best interests of the Company, its stakeholders and shareholders. The Executive Directors strive to act in a manner which is professional and ethical and has published its ethical policies for all employees to observe and comply with.

PRINCIPLE 9: MAINTAIN GOVERNANCE STRUCTURES AND PROCESSES THAT ARE FIT FOR PURPOSE AND SUPPORT GOOD DECISION MAKING BY THE BOARD

Board programme

The Board meets regularly during the year in accordance with its scheduled meeting calendar.

The Board sets direction for the Company through a formal schedule of matters reserved for its decision and annually sets a schedule of dates for Board meetings.

The Board and its Committees receive appropriate and timely information prior to each meeting; a formal agenda is produced for each meeting, and Board and Committee papers are distributed prior to meetings taking place.

Any Director may challenge Company proposals and decisions are taken democratically after discussion. Any Director who feels that any concern remains unresolved after discussion may ask for that concern to be noted in the minutes of the meeting, which are then circulated to all Directors.

Any specific actions arising from such meetings are agreed by the Board or relevant Committee and then followed up by the Company's management.

Roles of the Board, Non-executive Chair and Chief Executive Officer

The Board is responsible for the long-term success of the Company. There is a formal schedule of matters reserved to the Board. It is responsible for overall Group strategy, approval of major investments (whether capex or opex), approval of the annual and interim results; annual budgets, dividend policy and Board structure.

It monitors the exposure to key business risks and reviews the strategic direction of all trading subsidiaries, their annual budgets and their performance in relation to those budgets.

The Non-executive Chair, together with the Non-executive Directors, are responsible for ensuring the maintenance of good corporate governance and challenging and discussing the strategic direction of the Company.

PRINCIPLE 9: CONTINUED

The Chief Executive Officer is responsible for the strategic direction of the Company and delivering against that strategy.

All Directors receive regular and timely information on the Group's operational and financial performance. Relevant information is circulated to the Directors in advance of meetings. The business reports regularly on its headline performance against its agreed budget, and the Board reviews the performance and any significant variances.

Executive Team

The Executive Team consists of Dr Stephen Hodge and Christopher Leigh. It is responsible for formulation of the proposed strategic focus for submission to the Board, the day-to-day management of the Group's businesses and its overall trading, operational and financial performance in fulfilment of that strategy, as well as plans and budgets approved by the Board of Directors. It also manages and oversees key risks, management development and corporate responsibility programmes. The Chief Executive Officer reports to the plc Board on issues, progress and recommendations for change with the Board as a whole being the final arbiter.

Board Committees

The Board is supported by the Audit and Remuneration Committees. Each Committee has access to such resources, information and advice as it deems necessary, at the cost of the Company, to enable the Committee to discharge its duties. Board nominations are dealt with by the Board as a whole.

PRINCIPLE 10: COMMUNICATE HOW THE COMPANY IS GOVERNED AND IS PERFORMING BY MAINTAINING A DIALOGUE WITH SHAREHOLDERS AND OTHER RELEVANT STAKEHOLDERS

The Company communicates with shareholders through the financial statements, full-year and half-year announcements, General Meetings (GM's) and the release of news via LSE channels together with occasional podcasts and webinars.

AUDIT COMMITTEE REPORT

SUSAN BOWEN
Chair of the Audit Committee

MEMBERSHIP
The Board has established an Audit Committee with the appropriate Terms of Reference, which is comprised of Susan Bowen (Chair), Sir Iain Gray CBE and Diane Savory OBE. The Committee reports to the Board in respect of its responsibilities.

RESPONSIBILITIES
The Committee meets, in conjunction with the Board, to discuss its ongoing responsibilities, including such matters as the existing risk management and internal control systems in place, its financial reporting obligations and external audit findings.

An outline of the key responsibilities undertaken by the Committee in the year are set out below:

- consider the appointment of the external auditors;
- discuss with the external auditors the nature and scope of the audit;
- review the half-year and annual financial statements;
- discuss matters arising from the external auditors' report to the Committee; and
- review the Company's statement on internal control.

INTERNAL CONTROLS
The Committee continues to monitor and review the Company's risks, financial reporting and internal control procedures through its regular Board meetings as a standard agenda item for discussion. It has been concluded that a separate internal audit function is not justified at this time because of the size and scope of the Company's business activities. However, as the Company grows the need for this function will be regularly assessed.

EXTERNAL AUDIT
The Board understands the importance of engaging with the external auditors and in order to support this relationship the external auditors are invited to attend at least one meeting of the Audit Committee each year. The Committee maintains the responsibility of making recommendations to the Board in respect of the appointment, re-appointment and removal of the external auditors. In the re-appointment of the auditors the Committee carefully considers their performance in discharging the audit, the terms of engagement and their independence as well as the commercial cost.

Susan Bowen
Chair of the Audit Committee

26 March 2025

REMUNERATION COMMITTEE REPORT

SIR IAIN GRAY CBE
Chair of the Remuneration Committee

MEMBERSHIP
The Board has established a Remuneration Committee with the appropriate Terms of Reference, which is comprised of Sir Iain Gray CBE (Chair), Susan Bowen and Diane Savory OBE. The Committee reports to the Board in respect of its responsibilities.

RESPONSIBILITIES
The Committee meets to:

- determine the remuneration and rewards for Executive Directors;
- maintain surveillance over all executive benefits including pensions;
- analyse information from external surveys; and
- ensure that remuneration policies for senior personnel facilitate employment and motivation.

Sir Iain Gray CBE
Chair of the Remuneration Committee

26 March 2025

DIRECTORS' REMUNERATION REPORT

The Directors present the Directors' Remuneration Report for the year ended 30 September 2024. This report has not been prepared in accordance with the Directors' Report Regulations because, as an AIM listed company, Versarien Plc does not fall within the scope of the regulations.

DIRECTORS' REMUNERATION

The Remuneration Committee comprises the Non-executive Chair, Diane Savory OBE, and the two Non-executive Directors, Sir Iain Gray CBE, who chairs the Committee, and Susan Bowen. The Remuneration Committee decides the remuneration policy that applies to Executive Directors.

SALARIES AND BENEFITS

The Remuneration Committee reviews the scale and structure of the Executive Directors' and senior employees' remuneration and the terms of their service or employment contracts, including share option schemes and other bonus arrangements.

CONTRACTS OF SERVICE

The Executive Directors Dr Stephen Hodge and Christopher Leigh each have a service agreement containing one year's notice. The Non-executive Directors, Diane Savory OBE, Sir Iain Gray CBE and Susan Bowen, have a service agreement with a three-month notice period.

DIRECTORS' INTERESTS – INTERESTS IN SHARE OPTIONS

Details of options held by Directors who were in office at 30 September 2024 are set out below.

Details of the Company's option schemes are set out in note 23 to the financial statements.

The market price of the Company's shares at 30 September 2024 was 0.06 pence. The range of market prices during the period was 1.19 pence to 0.06 pence.

DIRECTORS' INTERESTS – INTERESTS IN SHARES

Directors in office at 30 September 2024 had interests in the Ordinary shares of 0.01 pence each in the Company as displayed in the table below.

	2024 Number	2023 Number
Dr Stephen Hodge	**1,046,774**	1,046,774
Christopher Leigh	**1,315,000**	1,315,000
Diane Savory OBE	**81,000**	81,000

Sir Iain Gray CBE
Non-executive Director

26 March 2025

DIRECTORS' REMUNERATION

	Salary		Benefits		Total	
	12 months to 30 September 2024 £'000	12 months to 30 September 2023 £'000	**12 months to 30 September 2024 £'000**	12 months to 30 September 2023 £'000	**12 months to 30 September 2024 £'000**	12 months to 30 September 2023 £'000
Executive						
Stephen Hodge	**120**	120	**10**	10	**130**	130
Christopher Leigh	**184**	184	**12**	12	**196**	196
Neill Ricketts (resigned 14 July 2023)	**—**	139	**—**	5	**—**	144
	304	443	**22**	27	**326**	470
Non-executive						
Sir Iain Gray CBE	**—**	13	**—**	—	**—**	13
Susan Bowen	**—**	13	**—**	—	**—**	13
Diane Savory OBE	**—**	21	**—**	—	**—**	21
	—	47	**—**	—	**—**	47

DIRECTORS' INTERESTS IN SHARE OPTIONS

Director	Date of grant	Number	Exercise price	Expiry date
Christopher Leigh	2 October 2014	1,050,761	29.00p	2 October 2024
	2 October 2017	2,626,614	15.00p	2 October 2027
	30 August 2018	2,669,616	152.00p	30 August 2028
Stephen Hodge	26 April 2017	75,000	21.25p	26 April 2027
	7 December 2018	453,720	117.00p	7 December 2028

Included within the share based payment charge of £147,000 in the Group Statement of Changes in Equity (2023: £530,000) is £68,000 (2023: £222,000) in respect of Christopher Leigh and £12,000 (2023: £38,000) in respect of Stephen Hodge.

The Directors present their Annual Report on the affairs of the Group and the Company, together with the audited consolidated financial statements and the Independent Auditors' Report, for the period ended 30 September 2024.

REVIEW OF THE BUSINESS AND FUTURE DEVELOPMENTS

The Directors are required to present an extended business review reporting on the development and performance of the Group and the Company during the period and their positions at the end of the period. This requirement is met by the Strategic Report on pages 1 to 14.

RESEARCH AND DEVELOPMENT

Investing in research and development programmes delivers product innovation and manufacturing improvements within Versarien plc. Expenditure on research and development in the period amounted to £0.38 million (2023: £0.83 million), of which £nil has been capitalised (2023: £nil) as the Group focuses on commercialisation of its product portfolio.

DIRECTORS

The Directors of the Company who were in office during the period and up to the date of signing the financial statements are listed on pages 16 to 17. The Directors' Remuneration Report on page 23 gives details of salaries, benefits and interests in shares and share options.

DIRECTORS' INDEMNITIES

The Company has granted indemnities to each of its Directors in respect of losses arising out of or in connection with the execution of their powers, duties and responsibilities as Directors to the extent permitted by the Companies Act 2006 and the Company's Articles of Association. Such qualifying third party indemnity provision has been in force throughout the period and remains in force at the date of approving the Directors' Report. In addition, Directors and officers of the Company and its subsidiaries are covered by directors' and officers' liability insurance.

EMPLOYEES

The Group keeps its staff informed of matters affecting them through a series of informal meetings at which employees are encouraged to ask questions on any aspects of the business and at which they are updated on financial and economic factors that may affect Company performance.

RISK FACTORS

Information on the Group's principal risks and how they are mitigated is given in the Strategic Report.

TREASURY ACTIVITIES AND FINANCIAL INSTRUMENTS

It is the Group's policy not to speculate in derivative financial instruments. The Company is not exposed to significant foreign exchange risks. Further details on financial risk factors are included in note 1.

POLITICAL DONATIONS

No political contributions were made during the period (2023: £nil).

GOING CONCERN

These financial statements have been prepared on a going concern basis making the assumptions described in the Accounting Policies note on page 38. The note includes reference to material uncertainties in respect of going concern.

SIGNIFICANT SHAREHOLDINGS

In addition to the Directors' holdings disclosed in the Directors' Remuneration Report on page 23, holders of more than 3% of the issued 3,718,938,737 Ordinary shares of the Company at 31 December 2024 being the latest practicable date before the publication of this report, are listed below.

Fund Manager	Ordinary shares of 1p each	Percentage of issue share capital
Hargreaves Lansdown Stockbrokers	739,245,994	19.88%
Interactive Investor Services Limited	690,476,741	18.57%
Halifax Share Dealing Limited	278,204,162	7.48%
Barclays Stockbrokers Limited	273,910,973	7.37%
Mr Richard Wyn And Mrs Christiane Therese Jones	261,830,814	7.04%
AJ Bell Securities Limited	259,408,197	6.98%
Mr S Jawahar	127,549,588	3.43%

INDEPENDENT AUDITORS

A resolution to re-appoint BDO LLP as independent auditors will be proposed at the Annual General Meeting.

By order of the Board

Christopher Leigh
Company Secretary

26 March 2025

STATEMENT OF DIRECTORS' RESPONSIBILITIES
IN RESPECT OF THE FINANCIAL STATEMENTS

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors are required to prepare the group and company financial statements in accordance with UK adopted international accounting standards. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company and of the profit or loss of the group for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether they have been prepared in accordance with UK adopted international accounting standards subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the group and the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the requirements of the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Website publication
The directors are responsible for ensuring the annual report and the financial statements are made available on a website.

Financial statements are published on the company's website in accordance with legislation in the United Kingdom governing the preparation and dissemination of financial statements, which may vary from legislation in other jurisdictions. The maintenance and integrity of the company's website is the responsibility of the directors. The directors' responsibility also extends to the ongoing integrity of the financial statements contained therein.

DIRECTORS' CONFIRMATIONS
In the case of each director in office at the date the directors' report is approved:

- so far as the director is aware, there is no relevant audit information of which the group's and company's auditors are unaware; and
- they have taken all the steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the group's and company's auditors are aware of that information.

By order of the Board

Christopher Leigh
Company Secretary

26 March 2025

In our opinion:

- the financial statements give a true and fair view of the state of the Group's and of the Parent Company's affairs as at 30 September 2024 and of the Group's loss for the year then ended;
- the Group financial statements have been properly prepared in accordance with UK adopted international accounting standards;
- the Parent Company financial statements have been properly prepared in accordance with UK adopted international accounting standards and as applied in accordance with the provisions of the Companies Act 2006; and
- the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements of Versarien Plc (the 'Parent Company') and its subsidiaries (the 'Group') for the year ended 30 September 2024 which comprise the Group Statement of Comprehensive Income, the Group Statement of Financial Position, the Company Statement of Financial Position, the Group Statement of Changes in Equity, the Company Statement of Changes in Equity, the Statement of Group and Company Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and UK adopted international accounting standards and, as regards the Parent Company financial statements, as applied in accordance with the provisions of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs

(UK)) and applicable law. Our responsibilities under those standards are further described in the

Auditor's responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence
We remain independent of the Group and the Parent Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard as applied to listed entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Material uncertainty related to going concern
We draw attention to the going concern section of the accounting policies of the financial statements which indicates that the Group and the Parent Company are dependent on raising new equity funding and/or selling Total Carbide Limited by mid-May 2025, as well as achieving forecasted sales, to remain going concerns. These are not guaranteed. As stated in the going concern section of the accounting policies, these events and conditions, along with other matters as set forth in the going concern section of the accounting policies, indicate that a material uncertainty exists that may cast significant doubt on the Group and the Parent Company's ability to continue as going concerns. The financial statements do not include any adjustments that would result if the Company were unable to continue as a going concern. Our opinion is not modified in respect of this matter.

Given the material uncertainty noted above and our risk assessment, we considered going concern to be a key audit matter.

Our evaluation of the Directors' assessment of the Group and the Parent Company's ability to continue to adopt the going concern basis of accounting and in response to the key audit matter included:

- Obtaining an understanding of how the Directors undertook the going concern assessment process to determine if we considered it to be appropriate in the circumstances;
- Challenging the Directors' going concern assessment, including the reasonableness of assumptions and downside stress case sensitivities applied, using our underlying knowledge of the business;
- Testing of the mathematical accuracy, and consideration of the reasonableness, of the assumptions made and available headroom throughout the forecast period extending from the date of approval of the financial statements;
- Consideration of the key sensitivities applied in the cash flow model pertaining to revenue and cost base, the continued use of the finance facilities and management of the Group's and Company's cost base;
- Performing a detailed review of the revenue projections by prospective customer and evaluating the quantum and timing of forecast revenues and assessing the feasibility by reference to supporting documentation provided by management to demonstrate interest in placing future sales orders;
- Assessing the feasibility of raising new equity finance, both prior to mid-May 2025 and subsequently by reference to evidence supporting the status of negotiations with the third party and by consideration of the Group's track record of raising funds on the capital markets;
- Assessing the feasibility of the sale of Total Carbide Limited by reference to supporting documentation showing the status of the sales process;
- Analysing post year end trading results compared to forecast and current year to evaluate the accuracy and achievability of forecasts; and
- Assessing the completeness and accuracy of disclosures in relation to going concern and whether significant judgements have been appropriately disclosed.

In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Our responsibilities and the responsibilities of the Directors with respect to going concern are described in the relevant sections of this report.

INDEPENDENT AUDITORS' REPORT CONTINUED
TO THE MEMBERS OF VERSARIEN PLC

Overview

Coverage	85% (2023: 93%) of Group loss before tax 96% (2023: 99%) of Group revenue 94% (2023: 97%) of Group total assets		
Key audit matters		*2024*	*2023*
	Going concern (Group and Parent Company)	✓	✓
	Goodwill and intangible assets impairment assessment (group)	✓	✓
	Development costs intangible valuation and impairment assessment (group))		✓
	Recoverability of investment in subsidiary undertakings (parent)		✓
	Development costs intangible valuation assessment is no longer considered to be a key audit matter because the development projects are finalised and no further costs have been capitalised in the current year. Recoverability of investment in subsidiary undertakings is no longer considered to be a key audit matter because the carrying value of subsidiary undertakings was fully impaired in the prior year.		
Materiality	*Group financial statements as a whole* £105,000 (2023:£155,00) based on 1.6% (2023: 1.5%) of total assets		

An overview of the scope of our audit
Our Group audit was scoped by obtaining an understanding of the Group and its environment, including the Group's system of internal control, and assessing the risks of material misstatement in the financial statements. We also addressed the risk of management override of internal controls, including assessing whether there was evidence of bias by the Directors that may have represented a risk of material misstatement.

We determined that the group had 5 significant components, being AAC Cyroma Limited, Total Carbide Limited, 2-DTech Limited, Versarien Graphene Limited and the Versarien Plc parent company. A full scope audit was undertaken on each of the significant components, as well as Cambridge Graphene Limited which holds a material amount of the group's development intangibles. All work was performed by the Group engagement team.

We determined that the remaining components of the group were non-significant components and the Group engagement team performed analytical procedures in order to obtain sufficient appropriate audit evidence to support our opinion on the Group financial statements as a whole.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) that we identified, including those which had the greatest effect on: the overall audit strategy, the allocation of resources in the audit, and directing the efforts of the engagement team. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the Material uncertainty related to going concern section of our report, we have determined the matters below to be the key audit matters to be communicated in our report.

<table>
<tr><th>Key audit matter</th><th>How the scope of our audit addressed the key audit matter</th></tr>
<tr><td colspan="2">Impairment of fixed assets (group)
(see accounting policies, critical estimates and judgements in note 2 and note 12 Intangible assets and note 13 Property, Plant and Equipment)</td></tr>
<tr><td>In accordance with the requirements of IAS 36 Impairment of assets, management has performed impairment reviews in relation to assets held in the Group's cash generating units (CGUs).

Management has determined that there are 2 CGUs, being the graphene technology business and Total Carbide.

The carrying value of assets within the graphene technology business CGU is £3.62 million and the carrying value of the Total Carbide CGU is £0.45 million, after recording an impairment of £0.89 million.

The impairment reviews include significant estimates and judgements in respect of future growth rates and cash flows and the discount rate employed and is therefore deemed to be a key audit matter.</td><td>We obtained the Group's cash flow forecasts supporting its impairment review and evaluated the appropriateness of key assumptions. We assessed the methodology used by management and challenged and evaluated key inputs including:
› We verified the mathematical accuracy of the discounted cash flow ("DCF") impairment model's underlying calculations which had been split into two CGU's (Total Carbide Limited and the graphene businesses) and agreed the cash flow forecasts to the plan approved by the Board;
› We evaluated the appropriateness of forecast cash flows by understanding management's process for forecasting, examining the support for forecast cash flows;
› We compared the projected growth rates used to historical information. Growth rates of 2% perpetuity were used in the DCF model, post the five year period to 30 September 2029;
› We evaluated the appropriateness of discount rates used, which included comparing the rate used to a range provided by our valuation experts and applied sensitivities to the discount rates to ensure sufficient headroom;
› We performed a range of sensitivity analyses to assess the impact of reasonably possible changes in key assumptions, including the quantum and timing of future revenues received to those used by management; and
› We considered the market capitalisation of the group at the current date and its split across the CGU's, based on estimated valuations of Total Carbide Limited and graphene businesses.

Key observations:
Based on our audit work performed, we consider the estimates and judgements made by management in the CGU impairment assessment and evidence from market capitalisation to be reasonable.</td></tr>
</table>

INDEPENDENT AUDITORS' REPORT CONTINUED
TO THE MEMBERS OF VERSARIEN PLC

Our application of materiality
We apply the concept of materiality both in planning and performing our audit, and in evaluating the effect of misstatements. We consider materiality to be the magnitude by which misstatements, including omissions, could influence the economic decisions of reasonable users that are taken on the basis of the financial statements.

In order to reduce to an appropriately low level the probability that any misstatements exceed materiality, we use a lower materiality level, performance materiality, to determine the extent of testing needed. Importantly, misstatements below these levels will not necessarily be evaluated as immaterial as we also take account of the nature of identified misstatements, and the particular circumstances of their occurrence, when evaluating their effect on the financial statements as a whole.

Based on our professional judgement, we determined materiality for the financial statements as a whole and performance materiality as follows:

	Group financial statements		Parent company financial statements	
	2024 £'000	2023 £'000	2024 £'000	2023 £'000
Materiality	105,000	155,000	89,000	93,000
Basis for determining materiality	1.6% of total assets	1.5% of total assets	1.5% of total assets	1.5% of total assets
Rationale for the benchmark applied	Total assets was considered to be the most appropriate benchmark as the Group's core activity of commercialising Graphene technology remains in early-stage status and the value of the business is therefore considered to be principally reflected in the value of its, development projects and other intangible assets.		Total assets was considered to be the most appropriate benchmark as the parent company does not trade in its own right	
Performance materiality	£78,750	£100,750	£66,750	£60,450
Basis for determining performance materiality	75% of materiality	65% of materiality	75% of materiality	65% of materiality
Rationale for the percentage applied for performance materiality	The aggregation effect of planned procedures was deemed to be low, therefore the performance materiality threshold was set at 75%.	A lower threshold has been applied in recognition of this being the first year we have audited the group.	The aggregation effect of planned procedures was deemed to be low for the parent company, therefore the performance materiality threshold was set at 75%.	A lower threshold has been retained in recognition of this being the second year we have audited the group.

Component materiality
For the purposes of our Group audit opinion, we set materiality for each significant component of the Group, apart from the Parent Company whose materiality is set out above, based on a percentage of between 9% and 67% (2023: 7% and 37%) of Group materiality dependent on the size and our assessment of the risk of material misstatement of that component. Component materiality ranged from £9,000 to £70,000 (2023: £37,000 to £58,000). In the audit of each component, we further applied performance materiality levels of 75% (2023: 75%) of the component materiality to our testing to ensure that the risk of errors exceeding component materiality was appropriately mitigated.

Reporting threshold
We agreed with the Audit Committee that we would report to them all individual audit differences in excess of £3,150 (2023: £4,650). We also agreed to report differences below this threshold that, in our view, warranted reporting on qualitative grounds.

Other information
The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Other Companies Act 2006 reporting
Based on the responsibilities described below and our work performed during the course of the audit, we are required by the Companies Act 2006 and ISAs (UK) to report on certain opinions and matters as described below.

Strategic report and Directors' report	In our opinion, based on the work undertaken in the course of the audit: › the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and › the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements. In the light of the knowledge and understanding of the Group and Parent Company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the Directors' report.
Matters on which we are required to report by exception	We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion: › adequate accounting records have not been kept by the Parent Company, or returns adequate for our audit have not been received from branches not visited by us; or › the Parent Company financial statements are not in agreement with the accounting records and returns; or › certain disclosures of Directors' remuneration specified by law are not made; or › we have not received all the information and explanations we require for our audit.

Responsibilities of Directors
As explained more fully in the Statement of Directors' responsibilities, the Directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Group's and the Parent Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or the Parent Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Non-compliance with laws and regulations
Based on:

- Our understanding of the Group and the industry in which it operates;
- Discussion with management and those charged with governance; and
- Obtaining and understanding of the Group's policies and procedures regarding compliance with laws and regulations

we considered the significant laws and regulations to be the Companies Act 2006, the applicable accounting framework, UK tax legislation, the principles of the Quoted Companies Alliance Corporate Governance Code and the AIM Listing Rules.

The Group is also subject to laws and regulations where the consequence of non-compliance could have a material effect on the amount or disclosures in the financial statements, for example through the imposition of fines or litigations. We identified such laws and regulations to be UK employment law and applicable health and safety legislation.

Our procedures in respect of the above included:

- Review of minutes of meeting of those charged with governance for any instances of non-compliance with laws and regulations;
- Review of correspondence with regulatory and tax authorities for any instances of non-compliance with laws and regulations;

INDEPENDENT AUDITORS' REPORT CONTINUED
TO THE MEMBERS OF VERSARIEN PLC

- Review of financial statement disclosures and agreeing to supporting documentation;
- Involvement of tax specialists in the audit;
- Review of legal and professional fees expenditure accounts to understand the nature of expenditure incurred.

Fraud
We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included:

- Enquiry with management and those charged with governance regarding any known or suspected instances of fraud;
- Obtaining an understanding of the Group's policies and procedures relating to:
  - Detecting and responding to the risks of fraud; and
  - Internal controls established to mitigate risks related to fraud.
- Review of minutes of meeting of those charged with governance for any known or suspected instances of fraud;
- Discussion amongst the engagement team as to how and where fraud might occur in the financial statements;
- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud; and
- Considering remuneration incentive schemes and performance targets and the related financial statement areas impacted by these.

Based on our risk assessment, we considered the areas most susceptible to fraud to be a fraud risk in relation to revenue recognition, particularly in the in the period before year end, the costs capitalised as development costs and the risk of management override of controls.

Our procedures in respect of the above included:

- Testing a sample of journal entries throughout the year, which met a defined risk criteria, by agreeing to supporting documentation;
- Assessing significant estimates made by management for bias;
- Review of the revenue nominal accounts for any unusual transactions; and
- Testing of a sample of transactions in September 2024 to check that revenue had been recorded in the correct period.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members who were all deemed to have appropriate competence and capabilities and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities is available on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report
This report is made solely to the Parent Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Parent Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Parent Company and the Parent Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Greg Watts (Senior Statutory Auditor)
For and on behalf of BDO LLP, Statutory Auditor
Birmingham, UK

Date: 26 March 2025

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 SEPTEMBER 2024

	Note	2024 £'000	2023 £'000
Continuing operations			
Revenue	3	**2,424**	2,983
Cost of sales		**(1,730)**	(2,362)
Gross profit		**694**	621
Other operating income	4	**380**	138
Operating expenses (including exceptional items)	5	**(4,907)**	(14,368)
Loss from operations before exceptional items		**(2,990)**	(4,844)
Exceptional items	6	**(843)**	(8,765)
Loss from operations		**(3,833)**	(13,609)
Finance costs	7	**(472)**	(526)
Finance income	7	**10**	16
Loss before income tax		**(4,295)**	(14,119)
Income tax	9	**133**	86
Loss from continuing operations		**(4,162)**	(14,033)
Loss from discontinued operations	10	**(131)**	(146)
Loss for the year		**(4,293)**	(14,179)
Loss attributable to:			
– Owners of the parent company		**(4,121)**	(13,525)
– Non-controlling interest		**(172)**	(654)
		(4,293)	(14,179)
Loss per share attributable to the equity holders of the Company:			
Basic and diluted loss per share	11	**(0.33)p**	(5.49)p

There is no other comprehensive income for the period.

The accompanying notes are part of the financial statements.

GROUP STATEMENT OF FINANCIAL POSITION
AT 30 SEPTEMBER 2024

	Note	2024 £'000	2023 £'000
Assets			
Non-current assets			
Intangible assets	12	**2,300**	2,763
Property, plant and equipment	13	**1,627**	3,443
Trade and other receivables	14	**347**	36
		4,274	6,242
Current assets			
Inventory	16	**938**	1,528
Trade and other receivables	17	**1,281**	1,409
Assets held for sale	18	**—**	604
Cash and cash equivalents		**145**	596
		2,364	4,137
Total assets		**6,638**	10,379
Equity			
Called up share capital (Ordinary Shares)	22	**233**	3,308
Called up share capital (Deferred Shares)	22	**3,424**	–
Share premium account	22	**38,284**	36,724
Merger reserve		**1,017**	1,256
Share-based payment reserve		**5,436**	5,289
Accumulated losses		**(47,570)**	(43,382)
Equity attributable to owners of the parent company		**824**	3,195
Non-controlling interest		**(1,981)**	(2,115)
Total equity		**(1,157)**	1,080
Liabilities			
Non-current liabilities			
Trade and other payables	20	**637**	501
Deferred tax liabilities		**6**	6
Innovate Loan	21	**4,500**	5,000
Long-term borrowings	21	**475**	995
		5,618	6,502
Current liabilities			
Trade and other payables	19	**1,167**	1,479
Innovate Loan	21	**500**	—
Invoice discounting advances	21	**112**	762
Current portion of long-term borrowings	21	**398**	556
		2,177	2,797
Total liabilities		**7,795**	9,299
Total equity and liabilities		**6,638**	10,379

The accompanying notes are an integral part of these financial statements.

The financial statements on pages 32 to 62 were approved by the Board of Directors on 26 March 2025 and signed on its behalf by:

Dr Stephen Hodge
Chief Executive Officer

Christopher Leigh
Chief Financial Officer

Registered number 8418328

COMPANY STATEMENT OF FINANCIAL POSITION
AT 30 SEPTEMBER 2024

	Note	2024 £'000	2023 £'000
Assets			
Non-current assets			
Investment in subsidiaries	15	**—**	—
Intangible assets	12	**430**	364
Property, plant and equipment	13	**5**	27
Trade and other receivables	14	**6,768**	4,905
		7,203	5,296
Current assets			
Trade and other receivables	17	**503**	33
Assets held for sale	18	**—**	604
Cash and cash equivalents		**58**	274
		561	911
Total assets		**7,764**	6,207
Equity			
Called up share capital (Ordinary Shares)	22	**233**	3,308
Called up share capital (Deferred Shares)	22	**3,424**	–
Share premium account	22	**38,284**	36,724
Merger relief reserve		**964**	1,203
Other reserve		**(431)**	(431)
Share-based payment reserve		**5,436**	5,289
Accumulated losses		**(46,775)**	(46,443)
Total equity		**1,135**	(350)
Liabilities			
Non-current liabilities			
Trade and other payables	20	**623**	438
Long-term borrowings	21	**2**	20
Innovate Loan	21	**4,500**	5,000
		5,125	5,458
Current liabilities			
Trade and other payables	19	**985**	1,080
Innovate Loan	21	**500**	–
Current portion of long-term borrowings	21	**19**	19
		1,504	1,099
Total liabilities		**6,629**	6,557
Total equity and liabilities		**7,764**	6,207

The accompanying notes are an integral part of these financial statements. The Company has elected to take the exemption under Section 408 of the Companies Act to not present the Company Income Statement. The loss of the Company for the year was £571,000 (2023: £13,981,000).

The financial statements on pages 32 to 62 were approved by the Board of Directors on 26 March 2025 and signed on its behalf by:

Dr Stephen Hodge
Chief Executive Officer

Christopher Leigh
Chief Financial Officer

Registered number 8418328

GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 SEPTEMBER 2024

	Share capital £'000	Share premium account £'000	Merger reserve £'000	Share-based payment reserve £'000	Accumulated losses £'000	Non-controlling interest £'000	Total equity £'000
At 30 September 2022	1,941	34,961	1,256	4,759	(29,694)	(1,624)	11,599
Re-allocation of minority interest	—	—	—	—	(163)	163	—
Issue of shares (note 22)	1,367	1,763	—	—	—	—	3,130
Loss for the year	—	—	—	—	(13,525)	(654)	(14,179)
Share-based payments (note 24)	—	—	—	530	—	—	530
At 30 September 2023	3,308	36,724	1,256	5,289	(43,382)	(2,115)	1,080
Re-allocation of minority interest	—	—	—	—	(306)	306	—
Issue of shares (note 22)	349	1,560	—	—	—	—	1,909
Transfer of reserves for Sale of AAC	—	—	(239)	—	239	—	–
Loss for the year	—	—	—	—	(4,121)	(172)	(4,293)
Share-based payments (note 24)	—	—	—	147	—	—	147
At 30 September 2024	**3,657**	**38,284**	**1,017**	**5,436**	**(47,570)**	**(1,981)**	**(1,157)**

Included within the merger reserve is £53,000 in respect of the merger with Versarien Technologies Limited (now Versarien Graphene Limited) and £964,000 in respect of the acquisition of Total Carbide Ltd.

COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 SEPTEMBER 2024

	Share capital £'000	Share premium account £'000	Merger relief reserve £'000	Other reserve £'000	Share-based payment reserve £'000	Accumulated losses £'000	Total equity £'000
At 30 September 2022	1,941	34,961	1,203	(431)	4,759	(32,462)	9,971
Issue of shares (note 22)	1,367	1,763	—	—	—	—	3,130
Loss for the year	—	—	—	—	—	(13,981)	(13,981)
Share-based payments (note 24)	—	—	—	—	530	—	530
At 30 September 2023	3,308	36,724	1,203	(431)	5,289	(46,443)	(350)
Issue of shares (note 22)	349	1,560	—	—	—	—	1,909
Transfer of reserves for Sale of AAC	—	—	(239)	—	—	239	—
Loss for the year	—	—	—	—	—	(571)	(571)
Share-based payments (note 24)	—	—	—	—	147	—	147
At 30 September 2024	**3,657**	**38,284**	**964**	**(431)**	**5,436**	**(46,775)**	**1,135**

Other reserve represents the difference between the nominal value of shares on the acquisition of Versarien Graphene Limited (previously Versarien Technologies Limited) and the carrying amount of Versarien plc's share of the net assets of Versarien Graphene Limited at that date.

STATEMENT OF GROUP AND COMPANY CASH FLOWS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

	Note	**Group 2024 £'000**	Group 2023 £'000	**Company 2024 £'000**	Company 2023 £'000
Cash flows from operating activities					
Cash used in operations	26	**(1,402)**	(2,377)	**(609)**	(1,012)
Net Interest paid		**(314)**	(364)	**(159)**	(153)
Net cash used in operating activities		**(1,716)**	(2,741)	**(768)**	(1,165)
Cash flows from investing activities					
Loans to subsidiaries		**—**	—	**(1,576)**	(3,325)
Dividends received from subsidiary		**—**	—	**—**	899
Purchase of intangible assets		**(70)**	(149)	**(66)**	(86)
Purchase of property, plant and equipment		**(31)**	(187)	**—**	—
Proceeds from disposal of assets held for sale		**302**	—	**302**	—
Net cash outflow from discontinued operations		**(3)**	—	**—**	—
Net cash from/used in investing activities		**198**	(336)	**(1,340)**	(2,512)
Cash flows from financing activities					
Share issue		**2,020**	3,351	**2,020**	3,351
Share issue costs		**(110)**	(221)	**(110)**	(221)
Payments of CBILS		**(53)**	(99)	**—**	—
Principal payment of leases under IFRS 16		**(459)**	(811)	**(18)**	(18)
Invoice discounting loan (repayments)/proceeds		**(331)**	102	**—**	—
Net cash generated from financing activities		**1,067**	2,322	**1,892**	3,112
(Decrease) in cash and cash equivalents		**(451)**	(755)	**(216)**	(565)
Cash and cash equivalents at beginning of period		**596**	1,351	**274**	839
Cash and cash equivalents at end of period		**145**	596	**58**	274

The accompanying notes are an integral part of these financial statements.

The statement of cash flows includes the following amounts relating to discontinued operations.

	Group 2024 £'000	Group 2023 £'000
Operating activities	**103**	297
Financing activities	**(113)**	(293)
(Decrease)/increase in cash and cash equivalents	**(10)**	4

GENERAL INFORMATION

Versarien plc is a public limited company by shares and is incorporated and domiciled in the United Kingdom. The Company is registered in England and the address of its registered office is Units 1A-D, Longhope Business Park, Monmouth Road, Longhope, Gloucestershire GL17 0QZ. The nature of the Group's operations and its principal activities are set out in the Strategic Report on pages 1 to 14.

These financial statements are presented in Sterling, the currency of the primary economic environment in which the Group operates, and all values are rounded to the nearest thousand (£'000) except where otherwise stated.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies are summarised below. They have all been applied consistently throughout the period and the preceding year.

BASIS OF ACCOUNTING

The consolidated financial statements consolidate the results of the Company and its subsidiaries (together referred to as the "Group"). The Group and Company financial statements have been prepared in accordance with UK-adopted international accounting standards in conformity with the requirements of the Companies Act 2006. The financial statements have been prepared on a going concern basis under the historical cost convention, unless otherwise stated.

Both the Group and Company financial statements are prepared in Pounds Sterling, rounded to the nearest thousand, unless otherwise indicated.

The preparation of financial statements in accordance with UK-adopted international accounting standards requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts in the financial statements. The areas involving a higher degree of judgement or complexity, or areas where assumptions or estimates are significant to the financial statements are disclosed in note 2.

Going concern

The Company's going concern assessment has been performed as part of the Group's going concern assessment. As at 30 September 2024, the Group had net liabilities of £1.2 million. As at 25 March 2025 the Group has a current bank balance of £0.90 million and headroom on its invoice discounting facilities of £0.05 million totalling £0.95 million, which includes £0.6 million relating to specific grant funding to be used over the next 2 years. If no further external financing is received, with the free cash available of £0.35 million the group will cease to be able to pay its liabilities as they fall due by mid-May 2025.

In order to assess the appropriateness of preparing the financial statements on a going concern basis the Directors have prepared detailed projections of expected future cash flows for the period to 30 September 2026. Based on these projections, the Group needs to raise finance over the next 12 months in order to enable the Group to continue to pay its liabilities as they fall due. The sources of this funding requirement are expected to come from a combination of the following:

- The Board is currently in advanced discussions with a third party with a view to raising equity funding of £0.5 million before mid-May 2025 at a premium to the current share price, which if completed, will equate to approximately 15% of the Company's enlarged share capital. An additional fund raising is also forecast later in the next 12 months amounting to £0.2 million.
- Based on feedback from current testing and discussions with several prospective large customers it is forecast that the Group will achieve substantial growth in cash inflows of 1.0 million from graphene sales compared to current run rates. This equates to a c.600% increase in sales over the last 12 months or c.400% increase over the current sales run rate and reflects the fact that the group has now moved from a product development phase into a sales growth phase.
- The sale of Total Carbide Limited, a wholly owned subsidiary undertaking. An active sales process has commenced with a sale forecast in the foreseeable future.

In addition to the above sources of funds, The Directors have assumed in the cash flow forecast that Innovate UK will not demand early repayment of the £5 million loan as a result of any potential covenant breaches.

In the event that one or more of the above are not wholly successful, the Company would need to raise additional funds from the issue of new equity shares. The Company has a history of raising equity funding on a regular basis. In the last 18 months the company has completed 6 such fund raises realising £2.6 million.

ACCOUNTING POLICIES CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

The Directors have run plausible downside sensitivities against the base forecast model. These show:

- If no new funds are raised from either equity fund raises or the sale of Total Carbide Limited before mid-May 2025 then the Group will cease to be a going concern.
- Assuming the £0.5 million fund raising referred to above completes but there are no further funds raised the Group would need to achieve the full forecast growth in graphene sales of 700% over the next 12 months before the forecast model runs out of cash. In this scenario, as explained above, the Directors would consider a further equity fund raise, if required.
- In the event that the group raises equity funds and Total Carbide Limited is sold in the next 12 months, the forecast model would require significantly lower growth in graphene products sales before running out of cash in the next 12 months.

Given that the above actions are not directly within the Directors' control, they are not guaranteed and the expected cash inflows may not be realised.

Therefore, the Group and the Company are dependent on raising new equity funding and/or selling Total Carbide Limited by mid-May 2025, as well as achieving forecast sales, to remain going concerns. These are not guaranteed. This indicates that a material uncertainty exists which may cast significant doubt on the Group and the Company's ability to continue as a going concern. Therefore, the Group and the Company may be unable to realise their assets and discharge their liabilities in the normal course of business.

After due consideration, the Directors have concluded that it is appropriate to prepare the financial statements on a going concern basis. In making their going concern assessment, the Directors have a reasonable expectation that sufficient additional funding will be raised to enable the Group and the Company to meet their liabilities as they fall due for a period of at least 12 months from the date of approval of the financial statements. Accordingly, the financial statements have been prepared on the going concern basis. The financial statements do not include the adjustments that would result if the Group was unable to continue as a going concern.

New standards, amendments and interpretations
There are no IFRSs or IFRIC interpretations that are not yet effective that would be expected to have a material impact on the Group or Company.

BASIS OF CONSOLIDATION
The consolidated financial statements comprise the financial statements of the Company and its Subsidiaries drawn up to 30 September 2024.

Subsidiaries are all entities over which the Group has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Group controls another entity.

Inter-company transactions, balances, income and expenses on transactions between Group companies are eliminated. Profits and losses resulting from intercompany transactions that are recognised in assets are also eliminated. Accounting policies of Subsidiaries have been changed where necessary to ensure consistency with the politics adopted by the Group.

SEGMENTAL REPORTING
The Directors regard the Group's reportable segments of the business to be the development and supply of graphene materials ("Technology Business"), the manufacture of tungsten carbide hard wear products ("Mature Business") and holding company activities ("Central Activities"). The disposal of AAC Cyroma Ltd is disclosed as discontinued operations. The business has no significant geographical aspect. Costs are allocated to the appropriate segment as they arise with central overheads apportioned on the basis of estimated time spent by central staff on subsidiary affairs. This segmentation is consistent with internal reports to the chief operating decision maker for use in assessing business performance and allocating Group resources. The chief operating decision maker is the Chief Executive Officer of the Group and the activity of each segment is explained in the Strategic Report.

BORROWINGS
Borrowings, including invoice discounting facilities, are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in the Group Statement of Comprehensive Income over the period of the borrowings using the effective interest method.

PROVISIONS
Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount has been reliably estimated. Provisions are not recognised for future operating losses.

INTANGIBLE ASSETS

Goodwill

Goodwill arising on consolidation represents the excess of the consideration payable over the Group's interest in the fair value of the identifiable assets and liabilities of a subsidiary at the date of acquisition. Goodwill is recognised as an asset and reviewed for impairment annually. For the purposes of assessing impairment, assets are grouped into cash-generating units (CGUs) being the lowest levels for which there are separately identifiable cash flows. Any impairment is recognised immediately in the Group Statement of Comprehensive Income and is not subsequently reversed. When the Group disposes of an interest in a subsidiary, the value of goodwill is reduced by the proportion that relates to the interest being disposed of.

Acquired intangible assets

Intangible assets are recognised on business combinations if they are separable from the acquired entity or arise from other contractual/legal rights. The amounts ascribed to such intangibles are arrived at by using appropriate valuation techniques.

Amortisation of intangible assets is charged on a straight line basis over five years for development and licence costs and twelve and a half years for intellectual property costs.

RESEARCH AND DEVELOPMENT

In accordance with IAS 38, it is the Group's policy to recognise an intangible asset for development including attributable overheads of its product once the criteria have been met. Otherwise all costs in the research phase will be recognised in the Group Statement of Comprehensive Income for the period in which they are incurred. Costs that are directly attributable to the development phase of a product are recognised as intangible assets, provided they meet the following recognition requirements:

- completion of the intangible asset is technically feasible so that it will be available for use or sale;
- the Group intends to complete the intangible asset and use or sell it;
- the Group has the ability to use or sell the intangible asset;
- the intangible asset will generate probable future economic benefits. Among other things, this requires that there is a market for the output from the intangible asset or for the intangible asset itself, or, if it is to be used internally, the asset will be used in generating such benefits;
- there are adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the expenditure attributable to the intangible asset during its development can be measured reliably.

Development costs not meeting these criteria for capitalisation are expensed as incurred. Capitalised development costs are written off over a period of 5 years from the point at which the developed product is available for commercial sale.

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are stated at cost less depreciation and any provision for impairment.

DEPRECIATION

Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset on a straight line basis over its expected useful life. The rates of depreciation are as follows:

- Leasehold improvements – over the term of the lease
- Plant and equipment – 5, 15 or 20 years
- Fixtures and fittings – 3 to 5 years
- Right of use asset – over the term of the lease

IMPAIRMENT OF PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLES

At each balance sheet date, the Group reviews the carrying amounts of its property and equipment and intangible assets with finite lives to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss. Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Goodwill arising on acquisition is allocated to cash-generating units. The recoverable amount of the cash-generating unit to which goodwill has been allocated is tested for impairment annually, or on such other occasions that events or changes in circumstances indicate that it might be impaired. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. Impairment losses are recognised as an expense immediately.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. Impairment losses relating to goodwill are not reversed.

ACCOUNTING POLICIES CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

FINANCIAL INSTRUMENTS
Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, other than financial assets and financial liabilities at 'fair value through profit or loss' ('FVTPL'), are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are expensed as incurred.

Financial assets

Financial assets are classified into 'financial assets at FVTPL' and 'financial assets at amortised cost'. The classification is determined at the time of initial recognition and depends on the Group's business model for managing the financial assets and whether the contractual cash flows represent solely payments of principal and interest.

Financial assets at amortised cost

Assets at amortised cost are non-derivative financial assets where the objective is to hold these assets in order to collect contractual cash flows and the contractual cash flows are solely payments of principal and interest. The Group's financial assets at amortised cost comprise 'trade and other receivables excluding prepayments' and 'cash and cash equivalents'.

Impairment of financial assets

The Group recognises a loss allowance for expected credit losses on financial assets at amortised cost or at FVTPL. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. For trade receivables and contract assets, the Group recognises expected credit losses that will result from all possible default events over the expected life of a financial instrument's 'lifetime ECL'. For all other financial instruments, the Group recognises lifetime ECL only when there has been a significant increase in credit risk since initial recognition. If the credit risk on the financial instrument has not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at an amount equal to the portion of lifetime ECL that is expected to result from default events on the financial instrument that are possible within 12 months after the reporting date. In assessing whether the credit risk on a financial instrument has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial instrument at the reporting date with the risk of a default occurring on the financial instrument at the date of initial recognition. In making this assessment, the Group considers an actual or expected significant deterioration in the financial instrument's external credit rating where available: significant deterioration in external market indicators of credit risk for a particular financial instrument, e.g. a significant increase in the credit spread or the credit default swap prices for the debtor, indications that any debtor is experiencing significant financial difficulty, default or delinquency in payments, an increase in the probability that any debtor will enter bankruptcy, or other financial reorganisation, and where observable data indicate that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults.

Financial liabilities

Financial liabilities are classified as either financial liabilities at 'FVTPL' or 'liabilities at amortised cost'. Financial liabilities are recognised initially on the date at which the Group becomes party to the contractual provisions of the instrument.

Financial liabilities at amortised cost

The classification of financial liabilities at amortised cost is determined at the time of initial recognition. Financial liabilities at amortised cost, including borrowings, trade and other payables, excluding deferred income and lease liabilities (after the adoption of IFRS 16 on 1 April 2019), and are measured using the effective interest method, which calculates the amortised cost of a financial liability and allocates interest expense over its term. The effective interest rate discounts estimated cash payments (including all issuance discounts and transactions costs) through the expected life of the financial liability, to the net carrying amount on initial recognition. Borrowings, including extensions to existing agreements, are recognised initially at fair value, net of discounts and transaction costs incurred. Borrowings are subsequently carried at amortised cost. Any difference between the net proceeds and the redemption value is recognised in the Income Statement over the term of the borrowings using the effective interest method. Interest arising on financial instruments is recognised on an accruals basis. In assessing whether a debt alteration is to be treated as a modification or an extinguishment and new arrangement, an evaluation is made of the qualitative factors such as the underlying parties to the transaction and quantitative factors such as the impact on the net present value of remaining cash flows. A gain or loss is recognised immediately in the income statement at the date of the modification of a financial liability.

INVENTORIES
Inventory is valued at the lower of cost and net realisable value. Cost comprises all direct expenditure and production overheads based on a normal level of activity. Provision is made for obsolete, slow-moving and defective inventory. Cost is calculated on a first-in, first-out basis and net realisable value represents the estimated sales value less costs to completion.

TRADE AND OTHER RECEIVABLES
Trade and other receivables include assets held under amortised cost and financial assets held at fair value through profit and loss (FVTPL). Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business.

Trade and other receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method. The Group recognises expected credit losses that will result from all possible default events over the expected life of a financial instruments for all trade and other receivables.

CASH AND CASH EQUIVALENTS
Cash and cash equivalents comprise cash held by the Group and short-term bank deposits with an original maturity of three months or less. The carrying value of these assets approximates their fair value. Cash at bank earns interest at floating rates based on daily bank deposit rates.

TRADE PAYABLES
Trade payables are not interest bearing and are stated at their amortised cost.

EQUITY INSTRUMENTS
Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs.

CURRENT AND DEFERRED TAX
The tax expense for the period comprises current and deferred tax. Tax is recognised in the Group Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions, where appropriate, on the basis of amounts expected to be paid to the tax authorities.

Deferred taxation is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method.

Deferred taxation liabilities are generally recognised on all taxable temporary differences. Deferred taxation assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised.

Deferred taxation is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised based on tax laws and rates that have been enacted at the balance sheet date. The carrying value of deferred taxation assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available against which taxable temporary differences can be utilised. Deferred tax is charged or credited to the Group Statement of Comprehensive Income, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity.

SHARE-BASED PAYMENTS
The Group issues equity-settled share-based payments to certain employees. Equity-settled share-based payments are measured at fair value (excluding the effect of non-market-based vesting conditions) at the date of grant. The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight line basis over the vesting period, based on the Group's estimate of shares or options that will eventually vest.

Employer's National Insurance in the United Kingdom and equivalent taxes in other jurisdictions are payable on the exercise of certain share options. In accordance with IFRS 2, this is treated as a cash-settled transaction. A provision is made, calculated using the fair value of the Company's shares at the balance sheet date and pro-rated over the vesting period of the options.

Fair value is measured using either the Black-Scholes or Monte Carlo pricing model. The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.

ACCOUNTING POLICIES CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

REVENUE RECOGNITION
Revenue from the Technology Businesses comprise income arising from development contracts and licencing agreements together with sales of products including graphene and graphene powders and inks. Revenue from the Mature Businesses comprise income arising from sale of products.

The revenue recognised in any reporting period is based on the contracted delivery of performance obligations and an assessment of when control is transferred to the customer. To be recognised as a contract, there must be appropriate approval from both parties and clear identification of each party's rights under the agreement. The payment terms should be evident, with collection of consideration probable.

The Group's customer arrangements take a variety of forms, with typical contractual frameworks comprising master terms and purchase orders.

Revenue comprises the fair value of the consideration received or receivable for the sale of goods in the ordinary course of the Group's activities and is shown net of value-added tax, returns, rebates and discounts.

Revenue is recognised when the performance obligation in the contract has been performed and control has been passed (so 'point in time' recognition). The customer gains the right of control at the time the product has been delivered.

GRANT INCOME RECOGNITION
Grant income is recognised in the Group Statement of Comprehensive Income on a receivable basis. A grant, contribution or donated asset may be received subject to a condition that it be returned to the transferor if a specified future event does or does not occur. A return obligation does not arise until such time as it is expected that the condition will be breached and a liability is not recognised until that time. Such conditions do not prevent the grant, contribution or donated asset being recognised as income in the Statement of Comprehensive Income. Capital grants are recognised over the useful life of the funded asset.

Grant income is deferred until costs have been incurred or revenue is generated as a direct result of the research and development costs that have been capitalised. The deferred grant income is subsequently recognised as income in the Statement of Comprehensive Income.

FOREIGN CURRENCIES
Assets and liabilities in foreign currencies are translated into Sterling at the rates of exchange ruling at the Statement of Financial Position date. Transactions in foreign currencies are translated into Sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

LEASES
As a lessee, the Group assesses if a contract is or contains a lease at the inception of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Group recognises a right-of-use asset and a lease liability at the commencement date. The lease liability is initially measured at the present value of the lease payments that are not paid at that date, discounted using the interest rate implicit in the lease if that rate can be readily determined. If that rate cannot be readily determined, the Group uses the incremental borrowing rate. Lease liabilities are classified as part of borrowings. The associated right-of-use asset is capitalised equal to the lease liability and disclosed together with property, plant and equipment.

The right-of-use asset is subsequently depreciated on a straight-line basis over the lease term. Right of-use assets are also subject to testing for impairment if there is an indicator for impairment.

EXCEPTIONAL ITEMS
Exceptional items are defined as items of income and expenditure which, in the opinion of the Directors, are unusual in nature or of such significance that they do not reflect the underlying performance of the Group on an ongoing basis and, in order to give a full understanding of the Group's underlying financial performance, they require separate disclosure on the face of the Group Statement of Comprehensive Income in accordance with IAS 1 "Presentation of Financial Statements".

1. FINANCIAL RISK MANAGEMENT

Financial risk factors

The Group's business activities are set out on the inside front cover. These activities expose the Group to a number of financial risks. The following describes the Group's objectives, policies and processes for managing these risks and the methods used to measure them.

(a) Capital risk management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure.

In order to maintain or adjust the capital structure, the Group may issue new shares.

The Group monitors capital on the basis of its net cash position. Net cash is calculated as cash and cash equivalents less total borrowings.

The Group's net debt at the balance sheet date was:

	2024 £'000	2023 £'000
Total borrowings (note 21)	**5,985**	7,313
Cash and cash equivalents	**145**	596
Group net debt	**5,840**	6,717

There were no changes in the Group's approach to capital management during the period.

(b) Foreign currency risk

Foreign currency risk arises where sale or purchase transactions are undertaken in currencies other than the respective functional currencies of Group companies. The Group is exposed to the changes in foreign currency exchange rates between a number of different currencies but the Group's primary exposures relate to the Euro.

The Group's policy is not to hedge its exposure using financial instruments, but to mitigate exposure by natural hedges as far as possible. If the currencies to which the Group is exposed had strengthened by 10%, the reported loss after taxation would not have been materially different to that reported.

(c) Interest rate risk

The Group currently uses invoice discounting advances to fund working capital requirements and hire purchase to fund plant and machinery additions and holds surplus funds on deposit. Interest rate risks are not hedged. If the interest rates to which the Group is exposed had increased by 1%, the reported loss after taxation would not have been materially different to that reported.

(d) Credit risk

The Group's credit risk is primarily attributable to its trade receivables and other current assets. The amounts recognised in the balance sheet are net of provision for doubtful debts. Trade receivables are subject to credit limits. Credit risk associated with cash balances is managed by transacting with financial institutions of high quality.

The maximum exposure to credit risk for trade receivables and other current assets is represented by their carrying amount.

(e) Liquidity risk

The Group seeks to manage liquidity risk to ensure sufficient liquidity is available to meet the requirements of the business and to invest cash assets safely and profitably. The Board reviews regularly available cash to ensure there are sufficient resources for working capital requirements and to meet the Group's financial commitments.

At 30 September 2024 and 30 September 2023, all amounts shown in the Group Statement of Financial Position under current assets and current liabilities mature for payment within one year.

2. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS

Sources of estimation uncertainty

The preparation of the financial statements requires the Group to make estimates, judgements and assumptions that affect the reported amount of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. The Directors base their estimates on historical experience and various other assumptions that they believe are reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

2. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS CONTINUED

Critical accounting estimates and judgements

The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Estimates and judgements are continually made and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable in the circumstances.

As the use of estimates is inherent in financial reporting, actual results could differ from these estimates. The Directors believe the following to be the key areas of judgement and estimation:

Judgements

(i) Going concern

The Directors have concluded that it is appropriate to prepare the financial statements on a going concern basis, however there is a material uncertainty in this regard, as explained in detail in the going concern section of the summary of significant accounting policies.

(ii) Determination of cash generating units (CGUs)

The directors have concluded that there are two CGUs for the purposes of fixed assets impairment testing, being the combined graphene technology businesses and Total Carbide Limited.

(iii) Legal claims

As outlined in note 28, Contingent Liabilities, there are 3 legal claims against Group companies. Based upon legal advice received the Directors have concluded that no provision is necessary.

(iv) Amortisation of development costs

The Directors considered it appropriate to commence amortisation of development costs from the beginning of this financial year, reflecting the fact that the development products were available for use from that date, in accordance with the accounting policy.

Estimates

(i) Intangible assets impairment

Development costs are capitalised on the balance sheet following an assessment of the criteria in IAS 38. They are assessed on an ongoing basis to determine whether circumstances may change and could lead to potential impairment of the carrying value.

Further detail on key assumptions, including growth rates, discount rates and the time period of these value-in-use calculations, is given in note 12.

(ii) Useful economic lives of intangible and tangible assets

In relation to the Group's finite life, intangible assets and property, plant and equipment, useful economic lives and residual values of assets have been established using historical experience and an assessment of the nature of the assets involved.

Assets are assessed on an ongoing basis to determine whether circumstances exist that could lead to potential impairment of the carrying value of such assets.

(iii) Subsidiary and expected credit losses

An assessment is made of expected credit losses arising amounts due from Group undertakings. This is determined based upon estimates of future cashflows generated by subsidiaries and is benchmarked against the Group's market capitalisation as at the reporting date.

(iv) Deferred consideration in relation to the sale of AAC Cyroma Limited on 27 September 2024

The discount rate used to discount the above receivable to its present value has been estimated by the Directors based upon their assessment of the prevailing market rate for a similar instrument.

(v) Inventory provision

An assessment is made of the net realisable value of the Group's inventory and a provision is recorded to reduce the carrying value to the lower of cost or net realisable value based upon an estimate of future demand.

3. SEGMENTAL INFORMATION – BUSINESS AND GEOGRAPHICAL SEGMENTS

At 30 September 2024, the Group is organised into two business segments. Central costs are reported separately.

Information reported to the Group's Chief Executive Officer for the purposes of resource allocation and assessment of segment performance is focused on the two principal business segments of Technology and Mature Businesses, and, accordingly, the Group's reportable segments under IFRS 8 are based on these activities.

Segment profit/(loss) represents the profit/(loss) earned by each segment, including a share of central administration costs, which are allocated on the basis of time spent by central staff on subsidiary affairs. This is the measure reported to the Chief Executive Officer for the purposes of resource allocation and assessment of segment performance.

The disposal of AAC Cyroma Ltd completed during the period and is presented as discontinued operations.

The segment analysis for the year ended 30 September 2024 is as follows:

	Central £'000	Technology Businesses £'000	Mature Businesses £'000	Intra-group adjustments £'000	Total continuing operations	Discontinued Operations	Total £'000
Revenue	**—**	**384**	**2,040**	**—**	**2,424**	**2,584**	**5,008**
Gross profit/(loss)	**—**	**(65)**	**759**	**—**	**694**	**617**	**1,311**
Other operating income	**—**	**377**	**3**	**—**	**380**	**—**	**380**
Operating expenses	**(402)**	**(2,283)**	**(2,185)**	**(37)**	**(4,907)**	**(711)**	**(5,618)**
(Loss)/Profit from operations	**(402)**	**(1,971)**	**(1,423)**	**(37)**	**(3,833)**	**(94)**	**(3,927)**
Finance charge	**(169)**	**(237)**	**(56)**	**—**	**(462)**	**(37)**	**(499)**
Loss before tax	**(571)**	**(2,208)**	**(1,479)**	**(37)**	**(4,295)**	**(131)**	**(4,426)**
Total assets	**7,764**	**4,885**	**2,158**	**(8,169)**	**6,638**	**—**	**6,638**
Total liabilities	**(6,629)**	**(25,516)**	**(1,028)**	**25,378**	**(7,795)**	**—**	**(7,795)**
Net assets/(liabilities)	**1,135**	**(20,631)**	**1,130**	**17,209**	**(1,157)**	**—**	**(1,157)**
Capital expenditure	**67**	**7**	**27**	**—**	**101**	**—**	**101**
Depreciation/amortisation and impairment	**22**	**795**	**1,217**	**2**	**2,036**	**67**	**2,103**

The segment analysis for the year ended 30 September 2023 is as follows:

	Central £'000	Technology Businesses £'000	Mature Businesses £'000	Intra-group adjustments £'000	Total continuing operations	Discontinued Operations	Total £'000
Revenue	—	239	2,744	—	2,983	2,465	5,448
Gross profit/(loss)	—	(560)	1,182	(1)	621	540	1,161
Other operating income	—	133	5	—	138	—	138
Other losses	—	—	—	—	—	—	—
Operating expenses	(15,141)	(5,136)	(1,256)	7,165	(14,368)	(647)	(15,015)
(Loss)/Profit from operations	(15,141)	(5,563)	(69)	7,164	(13,609)	(107)	(13,716)
Finance charge	256	(690)	(76)	—	(510)	(39)	(549)
Loss before tax	(14,885)	(6,253)	(145)	7,164	(14,119)	(146)	(14,265)
Total assets	6,207	5,766	3,966	(6,986)	8,953	1,426	10,379
Total liabilities	(6,557)	(25,617)	(1,539)	25,429	(8,284)	(1,015)	(9,299)
Net assets/(liabilities)	(350)	(19,851)	2,427	18,443	669	411	1,080
Capital expenditure	87	391	9	—	487	—	487
Depreciation/amortisation and impairment	6,448	3,053	365	—	9,866	124	9,990

NOTES TO THE FINANCIAL STATEMENTS CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

3. SEGMENTAL INFORMATION – BUSINESS AND GEOGRAPHICAL SEGMENTS CONTINUED

Geographical information

The Group's continuing operations revenue from external customers and information about its segment assets by geographical location are detailed below:

	Revenue from external customers	
	Continuing 2024 £'000	Continuing 2023 £'000
United Kingdom	**1,573**	2,111
Rest of Europe	**420**	263
North America	**12**	–
Other	**419**	609
	2,424	2,983

	Non-current assets					
	Continuing 2024 £'000	**Discontinued 2024 £'000**	**Total 2024 £'000**	Continuing 2023 £'000	Discontinued 2023 £'000	Total 2023 £'000
United Kingdom	**4,097**	**—**	**4,097**	5,532	584	6,116
Rest of Europe	**18**	**—**	**18**	78		78
North America	**—**	**—**	**–**	—	—	–
Other	**159**	**—**	**159**	48		48
	4,274	**–**	**4,274**	5,658	584	6,242

4. OTHER OPERATING INCOME

	2024 £'000	2023 £'000
Grant income	**378**	131
Other income	**2**	7
	380	138

5. EXPENSES BY NATURE

Expenses included in operating expenses are analysed below:

	2024 £'000	2023 £'000
Operating expenses		
Employee costs (salaries, National Insurance and pension)	**2,787**	3,574
Share-based payments	**147**	530
Research and development	**384**	827
Depreciation and impairment of tangible assets	**1,570**	1,969
Loss on disposal of tangible assets	**119**	183
Loss on foreign currency translation	**58**	10
Amortisation and impairment of intangible assets	**533**	8,022
Non-audit services		
– Tax compliance fees	**27**	28
– R&D fees	**—**	41
Audit services:		
– Fees payable to the Company auditors for the audit of the parent company and consolidated financial statements	**42**	40
– The audit of the Company's subsidiaries pursuant to legislation	**96**	110

6. EXCEPTIONAL ITEMS

	2024 £'000	2023 £'000
Continuing Operations		
Goodwill impairment	**—**	3,132
Development cost impairment	**—**	1,864
Patent and trademarks impairment	**—**	2,724
Asset impairment	**888**	861
Deferred income related to development cost impairment	**—**	(238)
Restructuring costs	**308**	483
Gain on disposal of discontinued operations	**(353)**	—
Other	**—**	(61)
	843	8,765

7. FINANCE COSTS AND INCOME

Finance costs for continuing operations	2024 £'000	2023 £'000
Lease interest charges	**81**	105
Bank interest and charges	**391**	421
	472	526
Finance income for continuing operations		
Bank deposit income & Foreign exchange gains	**10**	16
Net finance charge	**462**	510

8. DIRECTORS AND EMPLOYEES

The average monthly number of employees, including Executive Directors, employed by the Group during the period was:

	Group 2024 Number	Company 2024 Number	Group 2023 Number	Company 2023 Number
Manufacturing	**40**	**—**	40	—
Sales, technical and administration	**24**	**4**	30	5
	64	**4**	70	5

The aggregate remuneration was as follows:

	Group 2024 £'000	Company 2024 £'000	Group 2023 £'000	Company 2023 £'000
Wages and salaries	**2,421**	**523**	3,115	755
Social security costs	**298**	**66**	386	93
Other pension costs	**68**	**6**	73	7
Share-based payment charge – equity settled	**147**	**147**	530	530
	2,934	**742**	4,104	1,385

Key management are considered to be the Executive Directors and their remuneration is included in the Directors' Remuneration Report on page 23. The total remuneration of Directors was £326,000 (2023: £517,000) and the highest paid Director earned £196,000 (2023: £196,000) plus pension contributions of £1,000 (2023: £1,000). Included within the share based payment charge is £145,000 in respect of the directors including £68,000 in respect of the highest paid director.

NOTES TO THE FINANCIAL STATEMENTS CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

9. INCOME TAX

	2024 £'000	2023 £'000
UK corporation tax on loss for the period	—	—
Research and development tax credits	133	86
Tax on loss on ordinary activities	133	86

The tax assessed for the period is higher (2023: higher) than the standard rate of corporation tax in the UK. The differences are explained below:

	2024 £'000	2023 £'000
Loss before tax	(4,295)	(14,119)
Loss before tax at the effective rate of corporation tax in the UK of 25% (2023: 19%)	(1,074)	(2,683)
Effects of:		
Expenses not deductible for tax purposes	—	1,108
Capital allowances in excess of depreciation and other timing differences	45	(92)
Unrelieved losses arising in the period	896	1,581
Tax credit for the period	(133)	(86)

In the financial year under review, the Group incurred a trading loss. The trading loss to be carried forward against future trading profits for corporation tax purposes is £20,551,000 (2023: £16,440,000). These losses will reduce the tax charge of future years until they are utilised provided future taxable profits are made. No deferred tax asset has been recognised, as there is currently insufficient certainty as to the precise timing of when the asset would be recovered. The unrecognised asset amounts to £4,009,000 (2023: £7,617,000), being £5,137,000 (2023: £8,359,000) of trading losses net against a capital allowances liability of £1,129,000 (2023: £742,000), leaving the remaining asset as unrecognised.

10. DISCONTINUED OPERATIONS

In September 2024 the Group sold its 100% interest in AAC Cyroma Ltd, which is the only operation presented as discontinued in 2024.

	2024 £'000
Total consideration (deferred and discounted)	450
Net assets disposed:	
Property, plant & equipment	158
Inventories	300
Trade and other receivables	624
Net cash outflow on discontinued operations	3
Trade and other payables	(622)
Loans	(47)
Invoice finance	(319)
Net assets on disposal	97
Gain on disposal of discontinued operation	353

10. DISCONTINUED OPERATIONS CONTINUED

	12 months to 2024 £'000	12 months to 2023 £'000
Result of discontinued operations		
Revenue	**2,584**	2,465
Cost of sales	**(1,967)**	(1,925)
Gross profit	**617**	540
Operating expenses (including exceptional items)	**(711)**	(647)
Loss from operations	**(94)**	(107)
Finance costs	**(37)**	(39)
Finance income	**–**	–
Loss before income tax	**(131)**	(146)
Income tax	**–**	–
Loss from discontinued operations	**(131)**	(146)
Basic and diluted loss per share	**(0.01)p**	(0.06)p

11. BASIC AND DILUTED LOSS PER SHARE

The calculation of the basic loss per share for the year ended 30 September 2024 and the period ended 30 September 2023 is based on the losses attributable to the shareholders of the Versarien plc Group divided by the weighted average number of shares in issue during the period. The calculation of diluted loss per share is based on the basic loss per share adjusted to allow for the issue of shares on the assumed conversion of all dilutive options. However, in accordance with IAS 33 "Earnings per Share", potential Ordinary shares are only considered dilutive when their conversion would decrease the profit per share or increase the loss per share. As at 30 September 2024, there were 6,875,710 (2023: 12,914,730) potential Ordinary shares, which have been disregarded in the calculation of diluted loss per share as they were considered non-dilutive at that date.

	Loss attributable to owners of parent company £'000	Weighted average number of shares '000	Basic loss per share pence
Year ended 30 September 2024	**(4,121)**	**1,247,787**	**(0.33)p**
Year ended 30 September 2023	(13,525)	246,401	(5.49)

NOTES TO THE FINANCIAL STATEMENTS CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

12. INTANGIBLE ASSETS

Group	Goodwill £'000	Development Costs £'000	Patents, trademarks and other Intangibles £'000	Total £'000
Cost				
At 30 September 2022	4,431	5,549	4,667	14,647
Additions	—	—	149	149
At 30 September 2023	4,431	5,549	4,816	14,796
Additions	—	—	70	70
At 30 September 2024	**4,431**	**5,549**	**4,886**	**14,866**
Accumulated amortisation and impairment				
At 30 September 2022	1,299	1,400	1,312	4,011
Amortisation charge	—	1	301	302
Impairment	3,132	1,864	2,724	7,720
At 30 September 2023	4,431	3,265	4,337	12,033
Amortisation charge	—	455	25	480
Impairment	—	—	53	53
At 30 September 2024	**4,431**	**3,720**	**4,415**	**12,566**
Carrying value				
At 30 September 2024	**—**	**1,829**	**471**	**2,300**
At 30 September 2023	—	2,284	479	2,763

The amortisation charge is included within operating expenses in the Statement of Comprehensive Income (note 5).

12. INTANGIBLE ASSETS CONTINUED

Impairment

At the year end, the carrying value of intangible assets was reviewed for impairment in accordance with IAS 36 Impairment of Assets.

For the purposes of this impairment review assets are allocated to cash generating units(CGU). The directors have assessed that the group has 2 CGUs, being the graphene technology businesses and Total Carbide Limited. The Total Carbide Limited CGU has previously impaired all of its intangible assets and the impairment review of the tangible assets is included in note 13. The recoverable amount of the graphene technology businesses CGU has been determined using a value in use calculation, the key assumptions of which are discount rate and forecast revenue growth.

For the value in use basis the Group prepares cash flow forecasts based on financial projections covering a ten-year period which takes account of both past performance and expectations for future developments. Cash flows beyond the plan period are extrapolated using estimated long-term growth rates which do not exceed the long-term average growth rate for the market.

Graphene revenues are anticipated to grow significantly over the plan period with £1m growth forecast for year 1, a further £1.8m growth for year 2 and 32% per annum for years 3 to 10. The graphene industry market projections are for growth between 30%-40% per annum over the next 10 years. Cash flows after the ten year plan period are forecast to grow by 2% in perpetuity.

The Key assumptions to which the value in use calculation is most sensitive are those regarding the discount rate and forecast revenue growth. The pre-tax rate used to discount forecast cash flow is 11.5% (2023: 11.5%). These forecasts are supported by the market capitalisation of the group as at 30 September 2024 of £1.29 million and as at 25 March 2025 of £1.32 million, which exceeds the net liabilities of the group of £1.2 million as at the year-end.

Sensitivity analysis has been performed on the impairment assessment. The discount rate used of 11.5% would need to increase to 24% to eliminate the headroom to nil. The growth in graphene sales would need to be delayed by more than 6 months with a similar growth profile as above thereafter to eliminate headroom.

Company	Patents and Trademarks £'000
Cost	
At 30 September 2022	3,778
Additions	86
At 30 September 2023	3,864
Additions	66
At 30 September 2024	**3,930**
Accumulated amortisation and impairment	
At 30 September 2022	490
Amortisation charge	280
Impairment	2,730
At 30 September 2023	3,500
Amortisation charge	—
Impairment	—
At 30 September 2024	**3,500**
Net book value	
At 30 September 2024	**430**
At 30 September 2023	364

NOTES TO THE FINANCIAL STATEMENTS CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

13. PROPERTY, PLANT AND EQUIPMENT

Group	ROU asset £'000	Plant and equipment £'000	Leasehold improvements £'000	Total £'000
Cost				
At 30 September 2022	6,596	8,034	568	15,198
Additions	149	184	4	337
Disposals	(883)	(192)	(35)	(1,110)
Transfer of assets held for sale	—	(1,083)	—	(1,083)
At 30 September 2023	5,862	6,943	537	13,342
Additions	—	29	2	31
Disposals	(422)	—	—	(422)
Disposals from sale of AAC Cyroma Ltd	(2,536)	(242)	(149)	(2,927)
At 30 September 2024	**2,904**	**6,730**	**390**	**10,024**
Accumulated depreciation				
At 30 September 2022	3,807	5,318	212	9,337
Charge for the year	642	392	74	1,108
Disposals	(702)	(191)	(35)	(928)
Transfer of assets held for sale	—	(479)	—	(479)
Impairment	—	861	—	861
At 30 September 2023	3,747	5,901	251	9,899
Charge for the year	489	119	74	682
Disposals	(303)	—	—	(303)
Impairment	416	472	—	888
Disposals from sale of AAC Cyroma Ltd	(2,379)	(241)	(149)	(2,769)
At 30 September 2024	**1,970**	**6,251**	**176**	**8,397**
Net book value				
At 30 September 2024	**934**	**479**	**214**	**1,627**
At 30 September 2023	2,115	1,042	286	3,443

ROU assets

	Group 2024 £'000			Group 2023 £'000		
	Plant and equipment	**Buildings**	**Total**	Plant and equipment	Buildings	Total
Cost	**1,838**	**1,066**	**2.904**	4,263	1,599	5,862
Accumulated depreciation	**(1,354)**	**(616)**	**(1,970)**	(3,299)	(448)	(3,747)
Net book value	**484**	**450**	**934**	964	1,151	2,115

Impairment testing of Total Carbide Limited
The recoverable amount of the Total Carbide Limited CGU is based upon the directors' assessment of fair value less costs to sell. As a result an impairment charge of £0.9m (2023: £Nil) has been recognised.

13. PROPERTY, PLANT AND EQUIPMENT CONTINUED

Company	Plant and equipment £'000
Cost	
At 1 October 2022	1,228
Transfer of assets held for sale	(1,083)
At 30 September 2023	145
At 30 September 2024	**145**
Accumulated depreciation	
At 1 October 2022	284
Charge for the year	123
Impairment	190
Transfer of assets held for sale	(479)
At 30 September 2023	118
Charge for the period	22
Impairment	—
At 30 September 2024	**140**
Net book value	
At 30 September 2024	**5**
At 30 September 2023	27

14. NON-CURRENT TRADE AND OTHER RECEIVABLES

	Group 2024 £'000	Group 2023 £'000	**Company 2024 £'000**	Company 2023 £'000
Due from Group undertakings (net of provisions)	**—**	—	**6,456**	4,905
Deferred consideration*	**312**	—	**312**	—
Leasehold deposits	**35**	36	**—**	—
	347	36	**6,768**	4,905

* Deferred consideration relates to amounts due in respect of the disposal of AAC Cyroma Ltd, the full consideration is to be paid down by 16 quarterly payments of £34,375. The deferred consideration has been discounted to its net present value.

The expected credit loss provision against amounts due from group undertakings within the parent company has been determined based upon the expected future cash flows as derived from the value in use underpinned by the five year forecast model referred to in note 12.

NOTES TO THE FINANCIAL STATEMENTS CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

15. INVESTMENT IN SUBSIDIARIES

	Company 2024 £'000	Company 2023 £'000
Net book value		
At the start of the period	—	3,982
Impairment	—	(3,982)
At the period end	—	—

	Country of incorporation	Class of capital	Ownership Percentage	Non-controlling interest
Technology Business				
Versarien Graphene Limited – manufacture of graphene products	UK	Ordinary	100.0%	—
2-DTech Limited – development and supply of graphene powders	UK	Ordinary	85.0%	15.0%
Cambridge Graphene Limited – development and supply of graphene inks	UK	Ordinary	85.0%	15.0%
Gnanomat S.L. – development and supply of energy storage devices	Spain	Ordinary	90.0%	10.0%
Versarien Graphene Inc – supply of graphene products (dormant)	USA	Ordinary	100.0%	—
Versarien Graphene (Hong Kong) Limited – intermediate holding company	HK	Ordinary	100.0%	—
Beijing Versarien Technology Limited – supply of graphene products (dormant)	China	Ordinary	100.0%	—
Versarien Korea Limited – supply of CVD graphene	Korea	Ordinary	85.0%	15.0%
Mature Business				
Total Carbide Ltd – manufacture of tungsten carbide parts	UK	Ordinary	100.0%	—

The registered address of all UK subsidiaries is Unit 1a-d, Longhope Business Park, Gloucestershire, GL17 0QZ.

The registered address of Gnanomat S.L. is Parque Cientifico de Madrid, Campus de Cantoblanco, Calle Faraday, 7, 28049 Madrid, Spain.

The registered address of Versarien Graphene Inc is Capitol Services Inc, 1675 South State Street, Suite B, Dover, Kent County, Delaware 1901, USA.

The registered address of Versarien Graphene (Hong King) Limited is 18th Floor, United Centre, 95 Queensway, Hong Kong. The registered address of Beijing Versarien Technology Limited is A201- 9, Block A, No.6, Dongyi Xiang, South Yanshangang Road, Fangshan District, Beijing. The registered address of Versarien Korea Limited is 839-5 Banggyo-dong, Hwasung-si, Gyeonggi-do, Korea.

Non-controlling interest accumulated losses includes 2-DTech Limited £1.5 million (2023: £1.3 million), Gnanomat SL £0.0 million (2023: £0.5 million). Cambridge Graphene Limited £0.3 million (2023: £0.3 million) and Versarien Korea Limited £0.2 million (2023: £0.0 million). Respectively net liabilities at the balance sheet date were £9.2 million (2023: £8.8 million), £0.2 million (2023: £1.3 million), £2.3 million (2023: £1.9 million) and £1.5 million (2023: £1.2 million).

On 27 September 2024 the Company disposed of its entire shareholding of AAC Cyroma Ltd.

16. INVENTORY

	Group 2024 £'000	Group 2023 £'000	Company 2024 £'000	Company 2023 £'000
Raw materials	**463**	476	**—**	—
Work in progress	**262**	725	**—**	—
Finished goods	**213**	327	**—**	—
	938	1,528	**—**	—

Stock recognised in cost of sales during the period as an expense was £421,000 (2023: £481,000) for continuing operations.

17. TRADE AND OTHER RECEIVABLES

	Group 2024 £'000	Group 2023 £'000	Company 2024 £'000	Company 2023 £'000
Trade receivables	**307**	1,037	**—**	—
Other debtors	**636**	126	**335**	19
Deferred consideration	**138**	—	**138**	—
Prepayments	**200**	246	**30**	14
	1,281	1,409	**503**	33

	Group 2024 £'000	Group 2023 £'000	Company 2024 £'000	Company 2023 £'000
Trade receivables not past due	**316**	1,046	**—**	—
Trade receivables past due but not impaired	**—**	—	**—**	—
Gross trade receivables at 30 September	**316**	1,046	**—**	—
Provision for bad debt at 1 October	**(9)**	(9)	**—**	—
Debt provisions recognised in the period	**—**	—	**—**	—
Provision for bad debt at 30 September	**(9)**	(9)	**—**	—
Net trade receivables at 30 September	**307**	1,037	**—**	—

The Directors consider that the carrying amount of trade receivables approximates to their fair value due to the short-term nature of the current receivables. Debts provided for and written off are determined on an individual basis and included in operating expenses in the financial statements. The Group's maximum exposure on credit risk is fair value on trade receivables as presented in the foregoing table.

The gross carrying amounts of trade and other receivables are denominated in the following currencies:

	Group 2024 £'000	Group 2023 £'000	Company 2024 £'000	Company 2023 £'000
Sterling	**1,011**	1,332	**503**	33
Euro	**229**	60	**—**	—
Other	**41**	17	**—**	—
	1,281	1,409	**503**	33

NOTES TO THE FINANCIAL STATEMENTS CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

18. ASSETS HELD FOR SALE

	Group 2024 £'000	Group 2023 £'000	**Company 2024 £'000**	Company 2023 £'000
Plant and equipment	**—**	604	**—**	604

As announced 11 March 2024, these assets were sold to MCK Tech Co. Ltd for £604,000. At 30 September 2024 £302,000 was owing and this debt is included in trade and other receivables.

19. TRADE AND OTHER PAYABLES

	Group 2024 £'000	Group 2023 £'000	**Company 2024 £'000**	Company 2023 £'000
Trade payables	**526**	717	**157**	120
Taxation and social security	**136**	254	**11**	50
Payables to Group undertakings	**—**	—	**681**	881
Accruals and deferred income	**505**	508	**136**	29
	1,167	1,479	**985**	1,080

The Directors consider that the carrying amount of trade payables approximates to their fair value.

20. NON-CURRENT TRADE AND OTHER PAYABLES

	Group 2024 £'000	Group 2023 £'000	**Company 2024 £'000**	Company 2023 £'000
Deferred grant income	**9**	11	**—**	—
Deferred licence cost	**5**	52	**—**	—
Other	**623**	438	**623**	438
	637	501	**623**	438

21. BORROWINGS

	Group 2024 £'000	Group 2023 £'000	**Company 2024 £'000**	Company 2023 £'000
Invoice discounting facilities	**112**	762	**—**	—
Obligations under hire purchase contracts and similar arrangements	**873**	1,551	**21**	39
Innovate UK loan	**5,000**	5,000	**5,000**	5,000
	5,985	7,313	**5,021**	5,039

	Group 2024 £'000	Group 2023 £'000	**Company 2024 £'000**	Company 2023 £'000
Short-term borrowings	**112**	762	**—**	—
Current portion of long-term borrowings	**898**	556	**519**	19
Long-term borrowings	**4,975**	5,995	**4,502**	5,020
	5,985	7,313	**5,021**	5,039

21. BORROWINGS CONTINUED

Analysis of repayments	**Group 2024 £'000**	Group 2023 £'000	**Company 2024 £'000**	Company 2023 £'000
Invoice discounting facilities – within one year	**112**	762	**—**	—
Finance leases and hire purchase contracts:				
Within one year	**898**	556	**519**	19
In two to five years	**2,675**	995	**2,202**	20
Innovate UK loan in two to five years	**2,300**	5,000	**2,300**	5,000
	5,985	7,313	**5,021**	5,039

Invoice discounting facilities of £112,000 (2023: £762,000) are secured by debentures and charges over certain Group assets, and attract interest at 2.75% over currency base rate. Finance leases and hire purchase contracts of £259,000 (2023: £485,000) attract interest at 3.5% above the base rate. The loan repayments of the Innovate UK loan of £5,000,000 will commence in August 2026 and be paid quarterly over a subsequent period to November 2028. The loan attracts an interest rate of 7.4% per annum, with half of the interest having previously been deferred and repayment commencing in August 2026.

Due to the short-term nature of the invoice discounting facilities and hire purchase agreements, the carrying amounts are assumed to be the same as their fair values.

22. CALLED UP SHARE CAPITAL AND SHARE PREMIUM ACCOUNT

Group and Company

	Number of ordinary shares '000	Number of deferred shares £'000	Called up share capital ordinary £'000	Called up share capital deferred £'000	Called up share capital total £'000	Share premium £'000	Total £'000
At 30 September 2022	194,150	–	1,941	–	1,941	34,961	36,902
Issue of shares	136,629	–	1,367	–	1,367	1,763	3,130
At 30 September 2023	330,779	–	3,308	–	3,308	36,724	40,032
Issue of shares	2,003,544	–	349	–	349	1,560	1,909
Share split	–	826,949	(3,424)	3,424	–	–	–
At 30 September 2024	**2,334,323**	**826,949**	**233**	**3,424**	**3,657**	**38,284**	**41,941**

The called up share capital in the table above represents the total number of authorised, issued and fully paid Ordinary shares of 2,334,323,000 with a nominal value of 0.01p per share.

23. SHARE OPTIONS

The Company has an option scheme for Executive Directors and employees, the Versarien plc Share Option Plan, created on 12 June 2013. All options are granted at the market value of the shares at the date of grant. The share option scheme runs for a period of ten years. Employees are eligible to participate in the scheme at the invitation of the Board. No payment is required from option holders on the grant of an option. Performance conditions or market conditions are attached to 6,801,000 options (2023: 13,368,000 options).

Movements in the number of share options outstanding and their related weighted average exercise prices were as follows:

	2024 Weighted average exercise price in pence per share	**Options '000**	2023 Weighted average exercise price in pence per share	Options '000
At 1 October 2023	**78.02**	**13,973**	78.86	15,206
Lapsed	**(0.77)**	**(7.097)**	(0.84)	(1,233)
At 30 September 2024	**77.25**	**6.876**	78.02	13,973

Of the £6,876,000 outstanding options (2023: 13,973,000), 75,000 had vested at 30 September 2024 (2023: 604,000).

NOTES TO THE FINANCIAL STATEMENTS CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

23. SHARE OPTIONS CONTINUED

Share options outstanding at the end of the period have the following expiry dates and exercise prices:

Year of grant	Exercise period	Exercise price in pence per share	**2024 Number '000**	2023 Number '000
2013	2014—2023	12.25	**—**	199
2014	2015—2027	29.00	**1,051**	2,124
2017	2018—2027	21.25	**75**	75
2017	2020—2027	15.00	**2,626**	5,253
2018	2021—2028	152.00	**2.670**	5,339
2018	2020—2028	117.00	**454**	454
2019	2020—2024	126.50	**—**	529
2021	2021—2031	39.5	**—**	—
			6,876	13,973

The weighted average fair value of options granted to Executive Directors and employees is determined using the Black-Scholes or Monte Carlo valuation model. The significant inputs into the model were the exercise prices shown above, volatility of 41% to 61% depending upon date of grant, dividend yield of 0%, expected option life of three to five years and annual risk-free interest rate of 1.1% to 1.57%. Future volatility has been estimated based on comparable information rather than historical data.

24. OTHER RESERVES

The merger reserve was created on the reconstruction of the Group following the acquisition of Versarien Graphene Limited (previously Versarien Technologies Limited). The share-based payment reserve was created as a result of the issue of share options. The fair value of equity-settled share-based payments is expensed on a straight line basis over the vesting period and the amount expensed in each period is credited to the share-based payment reserve. The movement in reserves for the period ended 30 September 2023 and the year ended 30 September 2024 is set out in the Group Statement of Changes in Equity.

25. LEASING

The Group leases land and buildings on which the factories it operates are located, and assets acquired under hire purchase. Land and buildings lease contracts are typically for standard lease commercial periods.

Leases typically include a monthly payment. The Group has recognised a right-of-use asset and a leasing liability based on these payments.

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the lease payments. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee's incremental borrowing rate is used, being the rate the individual lease would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

To determine the incremental borrowing rate, the Group uses recent third party financing received by the individual as a starting point, adjusted to reflect changes in financing conditions since the third party financing was received. The Group had a range of borrowing rates from 4% to 6%. The Group believes that any reasonably possible change in the weighted average incremental borrowing rate would not cause the carrying value of lease liabilities or the lease interest payable charged to the Income Statement to be materially different.

Lease payments are allocated between principal and finance costs. The finance cost is charged to profit and loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. Right-of-use assets are depreciated over the lease term on a straight line basis.

The total cash outflow for leases in 2024 was £522,000 (2023: £713,000).

25. LEASING CONTINUED

The right-of-use asset recognised includes leases and hire purchase agreements. The leasing liabilities are included as follows in the statement of financial position:

Group	2024 £'000	2023 £'000
ROU liability under IFRS 16		
Lease liability – current	**284**	350
Lease liability – non-current	**330**	717
Borrowings – obligations under hire purchase contracts		
Current portion of long-term borrowings	**103**	126
Long-term borrowings	**129**	232
	846	1,425

The amounts below represent the minimum future lease payments, including interest:

Group	2024 £'000	2023 £'000
Net obligations repayable:		
Within one year	**441**	525
Between one and five years	**447**	992
	888	1,517

26. CASH USED IN OPERATIONS

	Group		Company	
	2024 £'000	2023 £'000	2024 £'000	2023 £'000
Loss for year (including discontinued operations)	**(4,293)**	(14,179)	**(571)**	(13,981)
Adjustments for:				
Share-based payments	**147**	530	**147**	530
Depreciation	**682**	1,108	**22**	123
Amortisation	**480**	302	**—**	280
Disposal of tangible assets	**–**	181	**—**	—
(Profit)/loss on disposal of discontinued operations	**(353)**	—	**(450)**	—
Impairment of tangible assets	**888**	861	**—**	191
Impairment of intangible assets	**53**	7,720	**—**	2,730
Impairment of investment in subsidiary	**—**	—	**—**	3,982
Dividend received from subsidiary	**—**	—	**—**	(899)
Finance cost/(income)	**499**	549	**169**	(262)
(Increase)/decrease in trade and other receivables and investments	**(56)**	771	**(31)**	6,370
Decrease in inventories	**290**	603	**—**	—
Increase/(decrease) in trade and other payables	**261**	(823)	**105**	(76)
Cash flows from operating activities	**(1,402)**	(2,377)	**(609)**	(1,012)

NOTES TO THE FINANCIAL STATEMENTS CONTINUED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

27. RELATED PARTY TRANSACTIONS

	Company	
	2024 £'000	2023 £'000
Service transactions charged to subsidiaries	**1,032**	2,147
Loans to subsidiaries	**1,121**	3,561
Repayments from subsidiaries	**(402)**	(1,174)
Subsidiaries balances written down	**—**	(6,333)
Year-end balance due from subsidiaries	**5,775**	4,905

28. CONTINGENT LIABILITY

Versarien Plc has received various unquantified claims under the Employment Rights Act 1996 against the Company and its directors made by a former director of the Company. The Company and its directors intend to vigorously defend the claims and continue to take legal advice. Following legal advice received around expected outcomes, no provision for any liability is recognised.

There are two separate employment claims against two Group companies, one in China (Beijing Versarien Technology Limited) which is dormant and the other in South Korea (Versarien Korea Limited). Should either or both of these claims be successful, neither of the Group companies have assets to settle any claims. The Group has received legal advice that the claims are only valid at subsidiary level and cannot be enforced against any other Group company; as such no provision is required in these Group accounts.

29. FINANCIAL INSTRUMENTS

Trade and other receivables (excluding prepayments) and cash and cash equivalents are classified as "amortised cost". Borrowings and trade and other payables are classified as "other financial liabilities at amortised cost". Both categories are initially measured at fair value and subsequently held at amortised cost.

The categories of financial instruments are as follows:

	Group 2024			Group 2023		
Financial assets	**Assets at amortised cost £'000**	**Assets at FVTPL £'000**	**Total £'000**	Assets at amortised cost £'000	Assets at FVTPL £'000	Total £'000
Cash and cash equivalents	**145**	**—**	**145**	596	—	596
Trade and other receivables excluding prepayments	**1,528**	**—**	**1,528**	1,199	—	1,199
Total at 30 September 2024	**1,673**	**—**	**1,673**	1,795	—	1,795

	Group 2024			Group 2023		
Financial liabilities	**Liabilities at amortised cost £'000**	**Liabilities at FVTPL £'000**	**Total £'000**	Liabilities at amortised cost £'000	Liabilities at FVTPL £'000	Total £'000
Trade and other payables excluding deferred income	**1,795**	**—**	**1,795**	1,789	—	1,789
Borrowings	**5,371**	**—**	**5,371**	6,247	—	6,247
Lease liabilities (IFRS 16)	**614**	**—**	**614**	1,067	—	1,067
Total at 30 September 2024	**7,780**	**—**	**7,780**	9,103	—	9,103

29. FINANCIAL INSTRUMENTS CONTINUED

Contracted maturities of financial liabilities

	Group 2024				Group 2023			
Financial liabilities	Within one year £'000	Between one and two years £'000	Between two and five years £'000	Total £'000	Within one year £'000	Between one and two years £'000	Between two and five years £'000	Total £'000
Trade and other payables excluding deferred income	**1,158**	**637**	**—**	**1,795**	2,058	52	—	2,110
Borrowings	**972**	**1,965**	**3,177**	**6,114**	1,154	1,155	5,613	7,922
Lease liabilities	**334**	**312**	**—**	**646**	399	399	361	1,159
Total at 30 September 2024	**2,464**	**2,914**	**3,177**	**8,555**	3,611	1,606	5,974	11,191

30. RECONCILIATION OF LIABILITY MOVEMENT AS A RESULT OF FINANCING ACTIVITIES

Group

	Non-Current Loans and borrowings £'000	Current Loans and borrowings £'000	Total £'000
As 30 September 2022	6,596	1,378	7,974
CIBLs repayments in period	(80)	(19)	(99)
Invoice discounting	—	102	102
Lease Liability transaction to IFRS 16	149	—	149
Lease Liability repayments in period	—	(813)	(813)
Loans classified as non-current at 30 September 2022 becoming current in period	(20)	20	—
Lease Liability classified as non-current at 30 September 2022 becoming current in period	(650)	650	—
As 30 September 2023	5,995	1,318	7,313
CIBLs repayments in period	(29)	(24)	(53)
CIBLs on sale of subsidiary	—	(47)	(47)
Invoice discounting	—	(331)	(331)
Invoice discounting on sale of subsidiary		(319)	(319)
Lease Liability transaction to IFRS 16	(269)	(64)	(333)
Termination of lease	(119)	—	(119)
Lease Liability repayments in period	(103)	(23)	(126)
As 30 September 2024	**5,475**	**510**	**5,985**

31. EVENTS SUBSEQUENT TO THE YEAR END

Since the year end the Group has raised £0.7 million gross via equity placings and has renewed its capital authorities for the issue of 3 billion shares without pre-emption rights.

In addition it has received £0.3 million to complete the sale of the Group's Korean plant and equipment and received £0.7 million grant funding in advance.

Innovate UK has also agreed to vary the terms of its £5 million loan such that capital and deferred interest repayments will commence in August 2026.

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the Annual General Meeting ("AGM") of Versarien plc (the "Company") will be held at the offices of FieldFisher LLP at Riverbank House, 2 Swan Lane, London, EC4R 3TT on 28 April 2025 at 10.30am for the following purposes:

ORDINARY BUSINESS

As ordinary business, to consider and, if thought fit, pass resolutions 1 to 3 inclusive, which will be proposed as ordinary resolutions:

1. To receive the Directors' Report and the audited financial statements for the year ended 30 September 2024 together with the Independent Auditors' Report thereon.
2. To re-appoint BDO LLP as the independent auditor of the Company for the year ending 30 September 2025 to hold office until the end of the next period for appointing the auditor in accordance with the provisions of Part 16 of the Companies Act 2006 and to authorise the Directors to fix the remuneration of the auditor for the year ending 30 September 2025 and for subsequent financial years or unless this authority is either revoked or varied.
3. To re-appoint Susan Bowen as a Director, retiring by rotation.

By order of the Board

Christopher Leigh
Company Secretary

26 March 2025

EXPLANATION OF RESOLUTIONS

These notes give an explanation of the proposed resolutions.

Resolutions 1 to 3 inclusive are proposed as ordinary resolutions. This means that for each of those resolutions to be passed, more than half of the votes cast must be in favour of the resolution.

ORDINARY RESOLUTIONS

Resolution 1 – Receipt of 2024 Annual Report and financial statements

The Directors of the Company must present the Directors' Report, the audited financial statements and the Independent Auditors' Report on those financial statements before shareholders each year at a general meeting. Those to be presented at the AGM are in respect of the year ended 30 September 2024.

Resolution 2 – Re-appointment of auditor

Resolution 2 proposes the re-appointment of BDO LLP as the Company's auditor and authorises the Directors to fix the remuneration of the auditor.

Resolution 3 – Re-appointment of Directors

The Articles of Association of the Company require the nearest number to, but not greater than, one-third of the Board of Directors to retire at each AGM with the longest serving retiring first. Any Director appointed to the Board since the last AGM has to retire at the next AGM but is not counted in the one-third to retire by rotation. Where the longest serving Directors have held office for the same amount of time, the Directors to resign are normally chosen by lot. Diane Savory and Susan Bowen have been the longest in office and Susan Bowen has been chosen by lot.

NOTES TO THE NOTICE OF THE ANNUAL GENERAL MEETING

ENTITLEMENT TO ATTEND AND VOTE

1. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, the Company specifies that only those members registered on the Company's register of members 48 hours prior to the date and time of the AGM, or, in the event that the AGM is adjourned, 48 hours (excluding non-working days) prior to the adjourned meeting, shall be entitled to attend and vote at the AGM in respect of the number of shares registered in their name at that time.

APPOINTMENT OF PROXIES

2. If you are a member of the Company at the time set out in note 1, above, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the AGM and you should have received a proxy form with this Notice of AGM. You can only appoint a proxy using the procedures set out in these notes and the notes to the proxy form. You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, please photocopy the proxy form.
3. A corporation which is a member can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a member provided that no more than one corporate representative exercises powers over the same share.
4. If you are not a member of the Company but you have been nominated by a member of the Company to enjoy information rights, you do not have a right to appoint any proxies under the procedures set out in this "Appointment of proxies" section. Please read the "Nominated persons" section (note 13).
5. A proxy does not need to be a member of the Company but must attend the AGM to represent you. Details of how to appoint the Chairman of the meeting or another person as your proxy using the proxy form are set out in the notes to the proxy form.

   If you wish your proxy to speak on your behalf at the AGM, you will need to appoint your own choice of proxy (not the Chairman) and give your instructions directly to them.
6. To direct your proxy how to vote on the resolutions, mark the appropriate box on your proxy form with an "X". To abstain from voting on a resolution, select the relevant "Vote withheld" box. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the AGM.

APPOINTMENT OF PROXY USING HARD-COPY PROXY FORM

7. The notes to the proxy form explain how to direct your proxy how to vote on each resolution or withhold their vote. To be valid, the proxy form, and any power of attorney or other authority (if any) under which it is executed (or a duly certified copy of such power or authority), must be duly completed, executed and deposited with the Company's registrars, Neville Registrars Limited, Neville House, Steelpark Road, Halesowen B62 8HD, or by scan and email to Neville Registrars Limited at info@nevilleregistrars.co.uk and in each case not less than 48 hours (excluding non-working days) before the time appointed for the AGM (or any adjourned meeting). In the case of a member which is a corporation, the proxy form must be executed under its common seal or signed on its behalf by an officer, attorney or other person duly authorised by the corporation.

NOTES TO THE NOTICE OF THE ANNUAL GENERAL MEETING CONTINUED

APPOINTMENT OF PROXIES THROUGH CREST

8. CREST members who wish to appoint a proxy or proxies by utilising the CREST electronic proxy appointment service may do so for the AGM and any adjournment(s) thereof by utilising the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s) who will be able to take the appropriate action on their behalf.

   In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message must be transmitted so as to be received by the issuer's agent, Neville Registrars Limited (CREST participant ID: 7RA11), by no later than 48 hours (excluding non-working days) before the time appointed for the AGM. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Application Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

   It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

   The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

APPOINTMENT OF PROXY BY JOINT MEMBERS

9. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first named being the most senior).

CHANGING PROXY INSTRUCTIONS

10. To change your proxy instructions, simply submit a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also applies in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded.

    Where you have appointed a proxy using the hard-copy proxy form and would like to change the instructions using another hard-copy proxy form, please contact Neville Registrars Limited (address in note 7).

    If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

TERMINATION OF PROXY APPOINTMENTS

11. In order to revoke a proxy instruction, you will need to inform the Company by sending a signed hard-copy notice clearly stating your intention to revoke your proxy appointment to Neville Registrars Limited (address in note 7). In the case of a member which is a corporation, the revocation notice must be executed under its common seal or signed on its behalf by an officer, attorney or other person authorised to sign the same. Any power of attorney or any other authority under which the revocation notice is signed (or a duly certified copy of such power or authority) must be included with the revocation notice.

    The revocation notice must be received by Neville Registrars Limited no later than 48 hours (excluding non-working days) before the time appointed for holding the AGM.

    If you attempt to revoke your proxy appointment but the revocation is received after the time specified then, subject to the paragraph directly below, your proxy appointment will remain valid.

    Appointment of a proxy does not preclude you from attending the AGM and voting in person. If you have appointed a proxy and attend the AGM in person, your proxy appointment will automatically be terminated.

ISSUED SHARES AND TOTAL VOTING RIGHTS

12. As at close of business on 25 March 2025 (being the latest practicable date prior to the publication of this document), the Company's issued share capital comprised 4,464,508,521 Ordinary shares of 0.01 pence each. Each Ordinary share carries the right to one vote at a general meeting of the Company and, therefore, the total number of voting rights in the Company as at close of business on 25 March 2025 is 4,464,508,521.

NOMINATED PERSONS

13. If you are a person who has been nominated under Section 146 of the Act to enjoy information rights:

- you may have a right under an agreement between you and the member of the Company who has nominated you to have information rights (the "Relevant Member") to be appointed or to have someone else appointed as a proxy for the AGM;
- if you either do not have such a right or if you have such a right but do not wish to exercise it, you may have a right under an agreement between you and the Relevant Member to give instructions to the Relevant Member as to the exercise of voting rights; and
- your main point of contact in terms of your investment in the Company remains the Relevant Member (or, perhaps, your custodian or broker) and you should continue to contact them (and not the Company) regarding any changes or queries relating to your personal details and your interest in the Company (including any administrative matters). The only exception to this is where the Company expressly requests a response from you.

COMMUNICATION

14. You may not use any electronic address provided either in:

- this Notice of Annual General Meeting; or
- any related documents (including the Chairman's letter and proxy form), to communicate with the Company for any purposes other than those expressly stated.

ADVISERS

REGISTRARS

Neville Registrars Limited

Neville House
Steelpark Road
Halesowen
B62 8HD

INDEPENDENT AUDITORS & TAX ADVISERS

BDO LLP

2 Snow Hill
Queensway
Birmingham
B4 6GA

NOMINATED ADVISER AND BROKER

SP Angel Corporate Finance LLP

Prince Frederick House
35–39 Maddox Street
London
W1S 2PP

LEGAL ADVISER

BPE Solicitors LLP

St James' House
St James' Square
Cheltenham
GL50 3PR

FINANCIAL PR

IFC Advisory Limited

Birchin Court
20 Birchin Lane
London
EC3V 9DU
W1T 3QE

SECRETARY AND REGISTERED OFFICE

Christopher Leigh

Longhope Business Park
Monmouth Road
Longhope
Gloucestershire
GL17 0QZ

Company registration number

8418328

WORLD LAND TRUST™
www.carbonbalancedpaper.com

FSC www.fsc.org RECYCLED Paper made from recycled material FSC® C022913

This report is printed on Revive 100% White Silk, a totally recycled paper produced using 100% recycled waste at a mill that has been awarded the ISO 14001 certificate for environmental management. The pulp is bleached using a totally chlorine free (TCF) process.

Designed and printed by:
perivan
perivan.com



VERSARIEN PLC

Longhope Business Park
Monmouth Road
Longhope
Gloucestershire
GL17 0QZ
www.versarien.com